



HOSPITAL-BASED CANCER REGISTRY

ANNUAL REPORT 2021



PHRAMONGKUTKLAO HOSPITAL

ARMY MEDICAL DEPARTMENT
MINISTRY OF DEFENCE
THAILAND

PHRAMONGKUTKLAO HOSPITAL EXCELLENT CENTER OF CANCER CARE

2021



Title

Phramongkutklao Hospital Cancer Registry
Report 2021

Editorial Board

Naiyarat Prasongsook, M.D.

Chairman of cancer Registry Committee,
Chairman Excellent Center of Cancer Care.

Kritsada Srithanaphakarangkul, M.D.

Chairman of Cancer of the Data
Information committee

Published by

Clinical Epidemiology Unit and Oncology
Department,

Phramongkutklao Hospital

315 Chalermprakiet Building, Ratchawithi Road,
Ratchathewi District, Thung Phaya Thai
Subdistrict. Bangkok 10400

Tel. : 02763 3925, 02763 3047

Published

2023

Edition

Fourteenth

Physical

71 pages



EXCELLENT CENTER OF CANCER CARE

HOSPITAL-BASED CANCER REGISTRY

ANNUAL REPORT

2021

Phramongkutklo Hospital
Royal Thai Army Medical Department
Ministry of Defence
Bangkok, Thailand

Edited By
Y. Tanapat and K. Sriphanaphakarangkul

Edition : December 2021

MESSAGE FROM DIRECTOR OF PHRAMONGKUTKLAO HOSPITAL



The Phramongkutklo Hospital is proud to present the Cancer Registry Report 2021. The report collects information on all new cancer cases. Data collected include the clinical characteristics of the cancer (site, histology, behavior, grade, extent of disease) and treatment details on the cancer patient. The registry has a comprehensive quality assurance program in place to ensure that the data are complete, accurate and timely.

I would like to thank all our collaborators for their dedication in providing data presented in this volume. I would like to express my gratitude to the devoted staffs of cancer registry in all cancer units for the immense amount of work that has been done in preparation of the statistics and graphics for this volume.

Thamrongroj Temudom Maj. Gen.
Director General of Phramongkutklo Hospital




INTRODUCTION

The Phramongkutklao Hospital Cancer Registry Report 2021 is a hospital-based cancer registry of new cancer patients initially diagnosed or initially treated at Phramongkutklao Cancer Center from January 1, 2021, to December 31, 2021. All new cancer patients registered during the mentioned period were treated at the various Cancer Units under The Excellent center of Cancer Care, Phramongkutklao Hospital. Patients were either primarily diagnosed or referred from army hospitals (under supervision of the Royal Thai Army Medical Department) as well as public and private hospitals. The objective of this is to report new cancer patients regarding method of diagnosis, pathological types, staging, behavior, grading, extension, and primary treatment modalities. Phramongkutklao Hospital has initiated a hospital cancer registry system based on the existing hospital data management system since 2009. This system has enabled physicians and nurses taking care of cancer patients to update patient information on the cancer registry at Cancer Units on a real-time basis. Thus, information obtained can be corrected and updated by persons in charge of patient care at the time of the patient's hospital visit. This process should contribute to the validity of information in the Cancer Registry.

This Cancer Registry Report would not be possible without the dedicated input of data from the staff of the Cancer Clinics and the Cancer Units from different departments at Phramongkutklao Cancer Center.



Assist. Prof. Naiyarat Prasongsook, M.D., M.S., COL.
Chairman Cancer Registry Committee
Phramongkutklao Cancer Center



EXCELLENT CENTER OF CANCER CARE PHRAMONGKUTKLAO HOSPITAL

1.	Maj.Gen.Thamrongroj	Temudom	Consultant
2.	Col. Pariyanan	Jaruchinda	Consultant
3.	Col. Rachata	Lumkul	Consultant
4.	Col. Kasan	Seetalarom	Consultant
5.	Col. Naiyarat	Prasongsook	Chairman of Administor Committee
6.	Col. Sukchai	Satthaporn.	Member
7.	Col. Chinakrit	BoonyaUssadorn	Member
8.	Col. Satit	Siriboonrid	Member
9.	Col. Sirinthip	Songwutwichai	Member
10.	Col. Chanchai	Traivaree	Member
11.	Col. Phutsapong	Srisawat	Member
12.	Lt.Col. Sithapan	Munjupong	Member
13.	Col. Kristsanamon	Rittiluechai	Member
14.	Lt.Col. Chonlada	Laoruagroj	Member
15.	Col. Vana	Sangsasri	Member
16.	Lt.Col. Jarey	Ketsirichai	Member
17.	Lt.Col. Siriwimon	Saichaemchan	Member
18.	Lt.Col. Watcharaporn	bourchom	Member
19.	Lt.Col. Kanya	Ketkong	Member
20.	Lt.Col. Nattapoang	Binsri	Member
21.	Lt.Col. Chalinee	Monseereenusorn	Member
22.	Lt.Col. Usa	Rittitada	Member
23.	Lt.Col. Supicha	Wongphun	Member



EXCELLENT CENTER OF CANCER CARE PHRAMONGKUTKLAO HOSPITAL

24.	Lt.Col. Kannadit	Prayongratana	Member
25.	Maj. Suvicha	Khampunnip	Member
26.	Maj. Sujitra	Shoolerd	Member
27.	Maj. Weerawan	Kaesai	Member
28.	Maj. Piyanuch	Srisuk	Member
29.	Maj. Nongnut	Seedapalee	Member
30.	Lt.Col. Rapeeporn	Kanchanapachana	Member
31.	Maj. Chetsuda	Khwanakorn	Member
32.	Capt. Sutipat	Pairojboriboon	Member
33.	Lt. Chatchanin	Ajalanond	Member
34.	Dr. Panjawit	Wuttipanich	Member
35.	Maj. wanvipa	Malaithong	Member
36.	Capt. Supittha	Tongpit	Member
37.	Maj. Phapasi	Punphasoed	Member
38.	Col. Jariya	Ketkao	Member
39.	Col. Waniknan	Hatsadin	Member
40.	Capt. Patcharaporn	liamsuwan	Member
41.	Capt. Atcharaporn	Sittichai	Member

CANCER REGISTRY STAFF

- | | | | |
|----|-----------------|----------|--------------------|
| 1. | Miss Rungthip | Boonyai | B.Com. (Computer) |
| 2. | Miss Chawanphat | Udomphon | B.Sc. (Statistics) |



TABLE OF CONTENTS

Title		
List of tables:		Page
Table 1	Distribution of new cancer patients by gender: 2021	1
Table 2	Number of all new patients: 2010-2021	2
Table 3	Ten leading primary sites of new cancer patients by gender: 2021	3
Table 4	Ten leading primary sites of new cancer patients in male: 2021	4
Table 5	Ten leading primary sites of new cancer patients in female: 2021	5
Table 6	Distribution of new cancer patients by age group and gender: 2021	6
Table 7	Distribution of new cancer patients by stage and gender: 2021	7
Table 8	Histologic differentiation of all solid cancer: 2021	8
Table 9	Immunophenotype designation for lymphomas and leukaemia: 2021	9
Table 10	Distribution of new cancer patients by extension and gender: 2021	9
Table 11	Distribution of new cancer patients by method and gender: 2021	10
Table 12	Distribution of new cancer patients by treatment modalities and gender: 2021	11
Table 13	Distribution of new cancer patients by treatment unit and gender: 2021	12
Table 14	Distribution of new cancer patients by status 2021	13
Table 15	Distribution of new cancer patients by follow up status and gender 2021	13
Table 16	Distribution of new military personnel cancer patients by age group and gender: 2021	14
Table 17	Distribution of new cancer patients by rank and gender: 2021	15
Table 18	Distribution of new childhood cancer patients (age 0-19) by age group and gender: 2021	16
Table 19	Distribution of new childhood cancer patients (age 0-19) by primary sites: 2021	16
Table 20	Distribution of new childhood cancer patients (age 0-19) by treatment modalities and gender: 2021	17
Table 21	Distribution of new childhood cancer patients (age 0-19) by method and gender: 2021	17
Table 22	Distribution of new childhood cancer patients (age 0-19) by type of extension and gender: 2021	18
Table 23	Distribution of new childhood cancer patients (age 0-19) by follow up and gender: 2021	18
Table 24	Number of new cancer patient stage and gender: 2021	19

TABLE OF CONTENTS

Title		
List of tables:		Page
Description of the leading site of cancers ordinal 1-3		
1. Breast cancer		
Table 25	Trend of breast cancer in Phramongkutklao hospital: 2010-2021	26
Table 26	Distribution of new breast cancer patients by age group and gender : 2021	27
Table 27	Distribution of new breast cancer patients by stage and gender: 2021	28
Table 28	Distribution of new breast cancer patients by method and gender: 2021	29
Table 29	Distribution of new breast cancer patients by extension and gender : 2021	29
Table 30	Distribution of new breast cancer patients by treatment modalities and gender: 2021	30
Table 31	Distribution of new breast cancer patients by follow up status and gender: 2021	30
2. Colon and rectum cancer		
Table 32	Trend of colon and rectum cancer in Phramongkutklao hospital: 2010-2021	31
Table 33	Distribution of new colon and rectum cancer patients by age group and gender: 2021	32
Table 34	Distribution of new colon and rectum cancer patients by stage and gender: 2021	33
Table 35	Distribution of new colon and rectum cancer patients by method and gender: 2021	34
Table 36	Distribution of new colon and rectum cancer patients by extension and gender: 2021	34
Table 37	Distribution of new colon and rectum cancer patients by treatment modalities and gender: 2021	35
Table 38	Distribution of new colon and rectum cancer patients by follow up status and gender: 2021	35
3. Trachea, bronchus, and lung cancer		
Table 39	Trend of trachea, bronchus, and lung cancer in Phramongkutklao hospital: 2010-2021	36
Table 40	Distribution of new trachea, bronchus and lung cancer patients by age group and gender: 2021	37
Table 41	Distribution of new trachea, bronchus and lung cancer patients by stage and gender: 2021	38
Table 42	Distribution of new trachea, bronchus and lung cancer patients by method and gender: 2021	39
Table 43	Distribution of new trachea, bronchus and lung cancer patients by extension and gender: 2021	39
Table 44	Distribution of new trachea, bronchus and lung cancer patients by treatment modalities and gender : 2021	40
Table 45	Distribution of new trachea, bronchus, and lung cancer patients by follow up status and gender: 2021	40

TABLE OF CONTENTS

Title		
List of tables:		Page
Description of the leading site of cancers ordinal 4-6		
4. Liver and intrahepatic bile ducts cancer		
Table 46	Distribution of new Liver and intrahepatic bile ducts cancer patients by age group and gender: 2021	41
Table 47	Distribution of new Liver and intrahepatic bile ducts cancer patients by stage and gender: 2021	42
Table 48	Distribution of new Liver and intrahepatic bile ducts cancer patients by method and gender: 2021	43
Table 49	Distribution of new Liver and intrahepatic bile ducts cancer patients by extension and gender: 2021	43
Table 50	Distribution of new Liver and intrahepatic bile ducts cancer patients by treatment modalities and gender: 2021	44
Table 51	Distribution of new Liver and intrahepatic bile ducts cancer patients by follow up status and gender : 2021	44
5. Prostate gland		
Table 52	Distribution of new Prostate gland cancer patients by age group and gender: 2021	45
Table 53	Distribution of new Prostate gland cancer patients by stage and gender: 2021	46
Table 54	Distribution of new Prostate gland cancer patients by method and gender: 2021	47
Table 55	Distribution of new Prostate gland cancer patients by extension and gender: 2021	47
Table 56	Distribution of new Prostate gland cancer patients by treatment modalities and gender: 2021	48
Table 57	Distribution of new Prostate gland cancer patients by follow up status and gender: 2021	48
6. NON-HODGKIN'S LYMPHOMA		
Table 58	Distribution of new Non - Hodgkin's Lymphoma cancer patients by age group and gender: 2021	49
Table 59	Distribution of new Non - Hodgkin's Lymphoma cancer patients by stage and gender: 2021	50
Table 60	Distribution of new Non - Hodgkin's Lymphoma cancer patients by method and gender: 2021	51
Table 61	Distribution of new Non - Hodgkin's Lymphoma cancer patients by extension and gender: 2021	51
Table 62	Distribution of new Non - Hodgkin's Lymphoma cancer patients by treatment modalities and gender: 2021	52
Table 63	Distribution of new Non - Hodgkin's Lymphoma cancer patients follow up status and gender: 2021	52

TABLE OF CONTENTS

Title		
List of tables:		Page
Number of cases by age-group in sex		
Table 64	Distribution of new cancer in male by age - group: 2021	53
Table 65	Distribution of new cancer in female by age - group: 2021	54
Distribution of new cancer in by morphology and site: 2021		
Table 66	Distribution of new cancer patients by morphology and site: 2021	55
Distribution of new cancer patients: 2017-2021		
Table 67	Distribution of new cancer patients by follow up and gender: 2017-2021	67
Table 68	The leading primary sites of new cancer by gender: 2017-2021	67
Table 69	The leading primary sites of new cancer by follow up and gender: 2017-2021	68
Table 70	The 60 months survival time (median) top 6 by gender in 2017 - 2021	68



FIGURE OF CONTENTS

Title		
List of figures:		Page
Figure 1	All new cancer cases in Phramongkutklao hospital :2010-2021	1
Figure 2	Trend of number of all new cancer patients by gender :2010-2021	2
Figure 3	Ten leading primary sites of new cancer patients by gender: 2021	3
Figure 4	Ten leading primary sites of new cancer patients in male: 2021	4
Figure 5	Ten leading primary sites of new cancer patients in female: 2021	5
Figure 6	Distribution of new cancer patients by age group and gender: 2021	6
Figure 7	Distribution of new cancer patients by stage and gender: 2021	7
Figure 8	Histologic differentiation of all solid cancer: 2021	8
Figure 9	Distribution of new cancer patients by extension and gender: 2021	9
Figure 10	Distribution of new cancer patients by method and gender: 2021	10
Figure 11	Distribution of new cancer patients by treatment unit and gender: 2021	12
Figure 12	Distribution of new cancer patients by follow up status: 2021	13
Figure 13	Distribution of new military personnel cancer patients by age group and gender: 2021	14
Figure 14	Distribution of new cancer patients by rank and gender: 2021	15



FIGURE OF CONTENTS

Title		
List of figures:		Page
Description of the leading site of cancers ordinal 1-3		
1. Breast cancer		
Figure 15	Distribution of new breast cancer patients by age group and gender : 2021	27
Figure 16	Distribution of new breast cancer patients by stage and gender: 2021	28
Figure 17	Distribution of new breast cancer patients by extension and gender : 2021	29
2. Colon and rectum cancer		
Figure 18	Distribution of new colon and rectum cancer patients by age group and gender: 2021	32
Figure 19	Distribution of new colon and rectum cancer patients by stage and gender: 2021	33
Figure 20	Distribution of new colon and rectum cancer patients by extension and gender: 2021	34
3. Trachea, bronchus, and lung cancer		
Figure 21	Distribution of new trachea, bronchus and lung cancer patients by age group and gender: 2021	37
Figure 22	Distribution of new trachea, bronchus and lung cancer patients by stage and gender: 2021	38
Figure 23	Distribution of new trachea, bronchus and lung cancer patients by extension and gender: 2021	39
4. Liver and intrahepatic bile ducts cancer		
Figure 24	Distribution of new Liver and intrahepatic bile ducts cancer patients by age group and gender: 2021	41
Figure 25	Distribution of new Liver and intrahepatic bile ducts cancer patients by stage and gender: 2021	42
Figure 26	Distribution of new Liver and intrahepatic bile ducts cancer patients by extension and gender: 2021	43
5. Prostate gland		
Figure 27	Distribution of new Prostate gland cancer patients by age group and gender: 2021	45
Figure 28	Distribution of new Prostate gland cancer patients by stage and gender: 2021	46
Figure 29	Distribution of new Prostate gland cancer patients by extension and gender: 2021	47
6. NON-HODGKIN'S LYMPHOMA		
Figure 30	Distribution of new Non - Hodgkin's Lymphoma cancer patients by age group and gender: 2021	49
Figure 31	Distribution of new Non - Hodgkin's Lymphoma cancer patients by stage and gender: 2021	50
Figure 32	Distribution of new Non - Hodgkin's Lymphoma cancer patients by extension and gender: 2021	51

FIGURE OF CONTENTS

Title		
List of tables:		Page
Number of cases by age-group in sex		
Distribution of the 60-month survival rate of cancers in : 2017-2021		
Figure 32	The 60 months survival rate (top 6) in 2017 – 2021	69
Figure 33	The 60 months survival rate (top 6) by male in 2017 – 2021	70
Figure 34	The 60 months survival rate (top 6) by Female in 2017 – 2021	71



2021 HOSPITAL-BASED CANCER REGISTRY ANNUAL REPORT



01

TABLE 1 DISTRIBUTION OF NEW CANCER PATIENTS BY GENDER : 2021	
Type of patients	Number of cases
Total new hospital patients	46,210 (100.00%)
Total new cancer patients	1,526 (3.30%)
Gender distribution of cancer	
• Male	771 (50.50%)
• Female	755 (49.50%)

FIGURE 1: ALL NEW CANCER CASE IN PHRAMONGKUTKLOA HOSPITAL: 2010 – 2021







TABLE 2 NUMBER OF ALL NEW PATIENTS : 2010 – 2021

Years	New patient	New cancer case	Case	Male		Female	
	Number	Number	Percent	Number	Percent	Number	Percent
2553 (2010)	48,054	1,640	3.41	847	1.76	793	1.65
2554 (2011)	50,148	1,730	3.45	927	1.85	803	1.60
2555 (2012)	58,244	1,898	3.26	985	1.69	913	1.57
2556 (2013)	66,151	1,801	2.72	897	1.36	904	1.37
2557 (2014)	68,306	1,856	2.72	947	1.39	909	1.33
2558 (2015)	55,484	1,536	2.77	801	1.44	735	1.32
2559 (2016)	59,191	1,771	2.99	881	1.49	890	1.50
2560 (2017)	58,320	1,539	2.64	779	1.34	760	1.30
2561 (2018)	55,771	1,666	2.99	886	1.59	780	1.40
2562 (2019)	57,049	1,720	3.01	885	1.55	835	1.46
2563 (2020)	42,412	1,608	3.79	800	1.89	808	1.91
2564 (2021)	46,210	1,526	3.30	771	1.77	755	1.74


FIGURE 2: TREND OF NUMBER OF ALL NEW PATIENTS BY GENDER: 2010 – 2021





Ordinal	Primary site	Male		Female		Total	
		Number	Percent	Number	Percent	Number	Percent
1	Breast	2	0.4	210	35.8	212	19.4
2	Colon & Rectum	117	23.2	82	14.0	199	18.2
3	Trachea, bronchus & lung	95	18.8	67	11.4	162	14.8
4	Liver & intrahepatic bile ducts	83	16.4	20	3.4	103	9.4
5	Prostate gland	97	19.2	0	0.0	97	8.9
6	Non-Hodgkin's lymphoma	45	8.9	51	8.7	96	8.8
7	Thyroid gland	14	2.8	79	13.5	93	8.5
8	leukaemia	29	5.7	21	3.6	50	4.6
9	Corpus uteri	0	0.0	41	7.0	41	3.8
10	Skin	23	4.6	16	2.7	39	3.6

FIGURE 3: TEN LEADING PRIMARY SITES OF NEW CANCER PATIENTS BY GENDER: 2021





Ordinal	Primary site	Number	Percent
1	Colon & Rectum	117	15.18
2	Prostate gland	97	12.58
3	Trachea, bronchus & lung	95	12.32
4	Liver & intrahepatic bile ducts	83	10.77
5	Non-Hodgkin's lymphoma	45	5.84
6	leukaemia	29	3.76
7	Oesophagus	27	3.50
8	Kidney, renal pelvis & ureter	24	3.11
9	Skin	23	2.98
10	Bladder	21	2.72

FIGURE 4: TEN LEADING PRIMARY SITES OF NEW CANCER PATIENTS IN MALE: 2021






TABLE 5 TEN LEADING PRIMARY SITES OF NEW CANCER PATIENTS IN FEMALE : 2021			
Ordinal	Primary site	Number	Percent
1	Breast	210	27.81
2	Colon & Rectum	82	10.86
3	Thyroid gland	79	10.46
4	Trachea, bronchus & lung	67	8.87
5	Non-Hodgkin's lymphoma	51	6.75
6	Corpus uteri	41	5.43
7	Cervix	23	3.05
8	Ovary	23	3.05
9	leukaemia	21	2.78
10	Liver & intrahepatic bile ducts	20	2.65

FIGURE 5: TEN LEADING PRIMARY SITES OF NEW CANCER PATIENTS IN FEMALE: 2021







TABLE 6 DISTRIBUTION OF NEW CANCER PATIENTS BY AGE GROUP AND GENDER : 2021						
Age group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
0-4	3	0.4	4	0.5	7	0.5
5-9	1	0.1	2	0.3	3	0.2
10-14	3	0.4	2	0.3	5	0.3
15-19	3	0.4	0	0.0	3	0.2
20-24	13	1.7	11	1.5	24	1.6
25-29	11	1.5	19	2.5	31	2.0
30-34	8	1.0	18	2.4	26	1.7
35-39	17	2.2	37	4.9	54	3.5
40-44	20	2.6	55	7.3	75	4.9
45-49	38	4.9	49	6.5	87	5.7
50-54	53	6.9	69	9.1	122	8.1
55-59	97	12.6	113	15.0	210	13.8
60-64	112	14.5	101	13.4	212	13.9
65-69	130	16.9	92	12.2	222	14.5
70-74	105	13.6	68	9.0	173	11.3
75-79	57	7.4	48	6.4	105	6.9
80-84	59	7.7	50	6.6	109	7.1
85+	41	5.3	17	2.3	58	3.8
Total	771	100.0	755	100.0	1526	100.0

Majority of cases

FIGURE 6: DISTRIBUTION OF NEW CANCER PATIENTS BY AGE GROUP AND GENDER: 2021








TABLE 7 DISTRIBUTION OF NEW CANCER PATIENTS BY STAGE AND GENDER : 2021						
Staging	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Stage I	127	16.5	227	30.1	354	23.2
Stage II	169	21.9	163	21.6	332	21.8
Stage III	160	20.8	151	20.0	311	20.4
Stage IV	266	34.5	186	24.6	452	29.6
No stage	49	6.4	27	3.6	76	5.0
Unknown	0	0.0	1	0.1	1	0.1
Total	771	100.0	755	100.0	1526	100.0

*No stage: manual system including leukaemia and brain

FIGURE 7: DISTRIBUTION OF NEW CANCER PATIENTS BY STAGE AND GENDER: 2021





HOSPITAL-BASED CANCER REGISTRY 2021 ANNUAL REPORT

Grade	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Well differentiated	70	10.1	77	11.3	147	10.7
Moderately differentiated	157	22.7	171	25.2	328	23.9
Poorly differentiated	205	29.7	190	28.0	395	28.8
Undifferentiated	53	7.7	8	1.2	61	4.5
Differentiated not Determined	206	29.8	233	34.3	439	32.0
Total	691	100.0	679	100.0	1370	100.0

FIGURE 8: HISTOLOGIC DIFFERENTIATION OF ALL SOLID CANCER: 2021







TABLE 9 IMMUNOPHENOTYPE DESIGNATION FOR LYMPHOMAS AND LEUKAEMIAS : 2021						
Immunophenotype designation	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
T – Cell	37	46.3	26	34.2	63	40.4
B – Cell	43	53.7	50	65.8	93	59.6
Total	80	100.0	76	100.0	156	100.0

TABLE 10 DISTRIBUTION OF NEW CANCER PATIENTS BY EXTENSION AND GENDER : 2021						
Extend	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Localized	452	58.6	480	63.6	932	61.1
Regional lymph nodes	103	13.4	122	16.2	225	14.7
Distant metastasis	216	28.0	153	20.2	369	24.2
Total	771	100.0	755	100.0	1526	100.0

FIGURE 9: DISTRIBUTION OF NEW CANCER PATIENTS BY EXTENSION AND GENDER: 2021





Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Radiology	21	2.7	21	2.8	42	2.8
Histopathology or Cytology	613	79.5	636	84.2	1249	81.8
Endoscopy	10	1.3	6	0.8	16	1.0
Bone marrow examination	78	10.1	81	10.7	159	10.4
Tumor marker	49	6.4	11	1.5	60	3.9
Total	771	100.0	755	100.0	1526	100.0

FIGURE 10: DISTRIBUTION OF NEW CANCER PATIENTS BY METHOD AND GENDER: 2021






TABLE 12 DISTRIBUTION OF NEW CANCER PATIENTS BY TREATMENT MODALITIES AND GENDER : 2021						
Treatment modality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery	259	33.6	230	30.4	489	32.0
Radiation	73	9.5	86	11.4	159	10.4
Chemotherapy	126	16.3	106	14.0	232	15.2
Hormone	1	0.1	2	0.3	3	0.2
Immunotherapy	12	1.6	14	1.9	26	1.7
Interventional	28	3.6	19	2.5	47	3.2
Surgery & Radiotherapy	36	4.7	48	6.4	84	5.6
Surgery & Chemotherapy	66	8.6	69	9.1	135	8.8
Radiation & Chemotherapy	21	2.7	30	4.0	51	3.3
Surgery & Radiotherapy & Chemotherapy	14	1.8	23	3.0	37	2.4
Counseling	135	17.5	128	17.0	263	17.2
Total	771	100.0	755	100.0	1526	100.0





Treatment unit	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Medicine oncology	279	36.2	231	30.5	510	33.4
Surgery oncology	385	49.9	290	38.4	675	44.2
Ear Nose and Throat oncology	61	7.9	51	6.8	112	7.3
Gynecologic oncology	0	0.0	88	11.7	88	5.8
Radiotherapy oncology	30	3.9	79	10.4	109	7.1
Pediatric oncology	7	0.6	8	1.1	15	1.0
Orthopedics oncology	9	1.2	8	1.1	17	1.2
Total	771	100.0	755	100.0	1526	100.0

FIGURE 11: DISTRIBUTION OF NEW CANCER PATIENTS BY TREATMENT UNIT AND GENDER: 2021







TABLE 14 DISTRIBUTION OF NEW CANCER PATIENTS BY STATUS : 2021						
Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Military	291	37.7	43	5.7	334	21.9
Civilian	480	62.3	712	94.3	1192	78.1
Total	771	100.0	755	100.0	1526	100.0

TABLE 15 DISTRIBUTION OF NEW CANCER PATIENTS BY FOLLOW UP STATUS AND GENDER : 2021						
Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	546	70.8	627	83.0	1173	76.9
Deaths	225	29.2	128	17.0	353	23.1
Total	771	100.0	755	100.0	1526	100.0

Survey: 31 December 2021

FIGURE 12: DISTRIBUTION OF NEW CANCER PATIENTS BY FOLLOW UP STATUS: 2021







TABLE 16 DISTRIBUTION OF NEW MILITARY PERSONNEL CANCER PATIENTS BY AGE GROUP AND GENDER : 2021						
Age group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 – 24	0	0.0	0	0.0	0	0.0
25 – 29	4	1.4	0	0.0	4	1.2
30 – 34	4	1.4	1	2.3	5	1.5
35 – 39	3	1.0	1	2.3	4	1.2
40 – 44	3	1.0	2	4.7	5	1.5
45 – 49	5	1.7	3	7.0	8	2.4
50 – 54	13	4.5	3	7.0	16	4.8
55 – 59	11	3.8	5	11.6	16	4.8
60 – 64	35	12.0	11	25.6	46	13.8
65 – 69	58	19.9	7	16.3	65	19.5
70 – 74	46	15.8	6	14.0	52	15.6
75 – 79	36	12.4	2	4.7	38	11.4
80 – 84	25	8.6	2	4.7	27	8.1
85 +	27	9.3	0	0.0	27	8.1
Total	21	7.2	0	0.0	21	6.3

Majority of cases

FIGURE 13: DISTRIBUTION OF NEW MILITARY PERSONNEL CANCER PATIENTS BY AGE GROUP AND GENDER: 2021





Rank	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Major General – General	53	18.2	10	23.3	63	18.9
Major – Colonel	95	32.6	21	48.8	116	34.7
Sub Lieutenant – Captain	93	32.0	5	11.6	98	29.3
Sergeant Major 3 rd - Sergeant Major 1 st	34	11.7	5	11.6	39	11.7
Private 1 st class – Sergeant	11	3.8	2	4.7	13	3.9
Enlisted Soldier	5	1.7	0	0.0	5	1.5
Total	291	100.0	43	100.0	334	100.0

FIGURE 14: DISTRIBUTION OF NEW CANCER PATIENTS BY RANK AND GENDER: 2021






TABLE 18 DISTRIBUTION OF NEW CHILDHOOD CANCER PATIENTS (AGE 0 - 19) BY AGE GROUP AND GENDER : 2021						
Age group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
0 – 4	3	30.0	4	50.0	7	38.8
5 – 9	1	10.0	2	25.0	3	16.7
10 – 14	3	30.0	2	25.0	5	27.8
15 - 19	3	30.0	0	0.0	3	16.7
Total	10	100.0	8	100.0	18	100.0

TABLE 19 DISTRIBUTION OF NEW CHILDHOOD CANCER PATIENTS (AGE 0 - 19) BY PRIMARY SITES : 2021					
Ordinal	Primary site	Male	Female	Total	
		Number	Number	Number	Percent
1.	Bone & articular cartilage	1	1	2	11.1
2.	Brain	1	0	1	5.6
3.	Intrathoracic organs	2	0	2	11.1
4.	Kidney, renal pelvis & ureter	0	1	1	5.6
5.	leukaemia	4	4	8	44.4
6.	Nasal cavity & accessory sinuses	1	0	1	5.6
7.	Non-Hodgkin's lymphoma	1	2	3	16.6
Total		10	8	18	100.0






TABLE 20 DISTRIBUTION OF NEW CHILDHOOD CANCER PATIENTS (AGE 0 - 19) BY TREATMENT MODALITIES AND GENDER : 2021						
Treatment modality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery	3	30.0	1	12.5	4	22.2
Chemotherapy	2	20.0	2	25.0	4	22.2
Surgery & Radiotherapy	0	0.0	1	12.5	1	5.6
Surgery & Chemotherapy	2	20.0	2	25.0	4	22.2
Surgery & Radiotherapy & Chemotherapy	0	0.0	1	12.5	1	5.6
Counseling	3	30.0	1	12.5	4	22.2
Total	10	100.0	8	100.0	18	100.0

TABLE 21 DISTRIBUTION OF NEW CHILDHOOD CANCER PATIENTS (AGE 0 - 19) BY METHOD AND GENDER : 2021						
Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Bone marrow	5	50.0	3	37.5	8	44.4
Histopathology or Cytology	5	50.0	5	62.5	10	55.6
Total	10	100.0	8	100.0	18	100.0





TABLE 22 DISTRIBUTION OF NEW CHILDHOOD CANCER PATIENTS (AGE 0 - 19)
BY TYPE OF EXTENSION AND GENDER : 2021

Spreading/Metastasis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Localized	10	100.0	7	87.5	17	94.4
Distant metastasis	0	0.0	1	12.5	1	5.6
Total	10	100.0	8	100.0	18	100.0

TABLE 23 DISTRIBUTION OF NEW CHILDHOOD CANCER PATIENTS (AGE 0 - 19)
BY FOLLOW UP AND GENDER : 2021

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	9	90.0	8	100.0	17	94.4
Deaths	1	10.0	0	0.0	1	5.6
Total	10	100.0	8	100.0	18	100.0

Survey: 31 December 2021





TABLE 24 NUMBER OF NEW CANCER PATIENTS STAGE AND GENDER : 2021

Site	Sex	Stage							
		I	II	III	IV	No stage	Un known	Total	
Adrenal gland	Male	-	1	-	-	1	-	2	
	Female	-	-	-	-	-	-	0	
	Total	(N)	-	1	-	-	1	-	2
		(%)	-	100.0	-	-	100.0	-	100.0
Anus & anus canal	Male	0	2	1	2	-	-	5	
	Female	1	2	1	2	-	-	6	
	Total	(N)	1	4	2	4	-	-	11
		(%)	100.0	100.0	100.0	100.0	-	-	100.0
Bladder	Male	5	6	7	3	-	-	21	
	Female	3	0	1	0	-	-	4	
	Total	(N)	8	6	8	3	-	-	25
		(%)	100.0	100.0	100.0	100.0	-	-	100.0
Bone & articular cartilage	Male	0	4	1	1	-	-	6	
	Female	2	2	1	2	-	-	7	
	Total	(N)	2	6	2	3	-	-	13
		(%)	100.0	100.0	100.0	100.0	-	-	100.0
Brain	Male	-	-	-	1	7	-	8	
	Female	-	-	-	0	1	-	1	
	Total	(N)	-	-	-	1	8	-	9
		(%)	-	-	-	100.0	100.0	-	100.0
Breast	Male	0	0	0	2	-	-	2	
	Female	68	63	43	36	-	-	210	
	Total	(N)	68	63	43	38	-	-	212
		(%)	100.0	100.0	100.0	100.0	-	-	100.0
Cervix	Male	-	-	-	-	-	-	0	
	Female	8	4	9	2	-	-	23	
	Total	(N)	8	4	9	2	-	-	23
		(%)	100.0	100.0	100.0	100.0	-	-	100.0



TABLE 24 NUMBER OF NEW CANCER PATIENTS STAGE AND GENDER : 2021

Site	Sex		Stage						
			I	II	III	IV	No stage	Un known	Total
Colon & Rectum	Male		17	28	29	43	-	-	117
	Female		10	22	25	25	-	-	82
	Total	(N)	27	50	54	68	-	-	199
		(%)	100.0	100.0	100.0	100.0	-	-	100.0
Corpus uteri	Male		-	-	-	-	-	-	0
	Female		26	5	5	6	-	-	42
	Total	(N)	26	5	5	6	-	-	42
		(%)	100.0	100.0	100.0	100.0	-	-	100.0
Female genital organs	Male		-	-	-	-	-	-	0
	Female		3	-	2	1	-	-	6
	Total	(N)	3	-	2	1	-	-	6
		(%)	100.0	-	100.0	100.0	-	-	100.0
Gall bladder & unspecified parts of biliary tract	Male		1	2	2	2	-	-	7
	Female		0	0	1	1	-	-	2
	Total	(N)	1	2	3	3	-	-	9
		(%)	100.0	100.0	100.0	100.0	-	-	100.0
Hodgkin's disease	Male		1	0	0	-	-	-	1
	Female		1	1	3	-	-	-	5
	Total	(N)	2	1	3	-	-	-	6
		(%)	100.0	100.0	100.0	-	-	-	100.0
Hypopharynx	Male		1	-	4	5	-	-	10
	Female		-	-	-	-	-	-	0
	Total	(N)	1	-	4	5	-	-	10
		(%)	100.0	-	100.0	100.0	-	-	100.0
Intrathoracic organs	Male		3	2	1	3	-	-	9
	Female		0	0	0	1	-	-	1
	Total	(N)	3	2	1	4	-	-	10
		(%)	100.0	100.0	100.0	100.0	-	-	100.0



TABLE 24 NUMBER OF NEW CANCER PATIENTS STAGE AND GENDER : 2021

Site	Sex	Stage							
		I	II	III	IV	No stage	Un known	Total	
Kidney, renal pelvis & ureter	Male	9	5	3	7	-	-	24	
	Female	2	4	2	2	-	-	10	
	Total	(N)	11	9	5	9	-	-	34
		(%)	100.0	100.0	100.0	100.0	-	-	100.0
Larynx	Male	4	2	3	5	-	-	14	
	Female	0	0	1	0	-	-	1	
	Total	(N)	4	2	4	5	-	-	15
		(%)	100.0	100.0	100.0	100.0	-	-	100.0
Leukaemia	Male	1	2	1	1	24	-	29	
	Female	0	1	1	0	19	-	21	
	Total	(N)	1	3	2	1	43	-	50
		(%)	100.0	100.0	100.0	100.0	100.0	-	100.0
Lip & Oral cavity	Male	2	2	7	8	-	-	19	
	Female	3	3	2	2	-	-	10	
	Total	(N)	5	5	9	10	-	-	29
		(%)	100.0	100.0	100.0	100.0	-	-	100.0
Mesothelial & soft tissue	Male	6	6	5	4	-	-	21	
	Female	2	9	1	3	-	-	15	
	Total	(N)	8	15	6	7	-	-	36
		(%)	100.0	100.0	100.0	100.0	-	-	100.0
multiple myeloma	Male	0	6	4	1	6	-	17	
	Female	2	0	7	0	3	-	12	
	Total	(N)	2	6	11	1	9	-	29
		(%)	100.0	100.0	100.0	100.0	100.0	-	100.0
Nasal cavity & accessory sinuses	Male	2	2	2	1	-	-	7	
	Female	1	0	0	2	-	-	3	
	Total	(N)	3	2	2	3	-	-	10
		(%)	100.0	100.0	100.0	100.0	-	-	100.0

TABLE 24

NUMBER OF NEW CANCER PATIENTS STAGE AND GENDER : 2021

Site	Sex	Stage							
		I	II	III	IV	No stage	Un known	Total	
Nasopharynx	Male	-	2	2	4	-	-	8	
	Female	-	0	3	0	-	-	3	
	Total	(N)	-	2	5	4	-	-	11
		(%)	-	100.0	100.0	100.0	-	-	100.0
Non-Hodgkin's lymphoma	Male	9	6	7	14	9	-	45	
	Female	10	12	11	15	3	-	51	
	Total	(N)	19	18	18	29	12	-	96
		(%)	100.0	100.0	100.0	100.0	100.0	-	100.0
Oesophagus	Male	2	2	9	14	-	-	27	
	Female	0	1	1	1	-	-	3	
	Total	(N)	2	3	10	15	-	-	30
		(%)	100	100.0	100.0	100.0	-	-	100.0
Oropharynx	Male	-	-	1	2	-	-	3	
	Female	-	-	1	0	-	-	1	
	Total	(N)	-	-	2	2	-	-	4
		(%)	-	-	100.0	100.0	-	-	100.0
Other and ill-defined digestive organs	Male	-	-	-	-	-	-	0	
	Female	-	-	-	1	-	-	1	
	Total	(N)	-	-	-	1	-	-	1
		(%)	-	-	-	100.0	-	-	100.0
Other endocrine glands and relate structures	Male	0	1	1	3	1	-	6	
	Female	1	0	1	1	0	-	3	
	Total	(N)	1	1	2	4	1	-	9
		(%)	100	100.0	100.0	100.0	100.0	-	100.0
Ovary	Male	-	-	-	-	-	-	0	
	Female	9	3	5	6	-	-	23	
	Total	(N)	9	3	5	6	-	-	23
		(%)	100.0	100.0	100.0	100.0	-	-	100.0



TABLE 24 NUMBER OF NEW CANCER PATIENTS STAGE AND GENDER : 2021

Site	Sex	Stage							
		I	II	III	IV	No stage	Un known	Total	
Pancreas	Male	4	2	4	8	-	-	18	
	Female	0	1	3	4	-	-	8	
	Total	(N)	4	3	7	12	-	-	26
		(%)	100.0	100.0	100.0	100.0	-	-	100.0
Prostate gland	Male	25	35	12	25	-	-	97	
	Female	-	-	-	-	-	-	0	
	Total	(N)	25	35	12	25	-	-	97
		(%)	100.0	100.0	100.0	100.0	-	-	100.0
Pyriform sinus	Male	-	-	1	-	-	-	1	
	Female	-	-	-	-	-	-	0	
	Total	(N)	-	-	1	-	-	-	1
		(%)	-	-	100.0	-	-	-	100.0
Liver & intrahepatic bile ducts	Male	10	26	23	24	-	-	83	
	Female	0	5	2	13	-	-	20	
	Total	(N)	10	31	25	37	-	-	103
		(%)	100.0	100.0	100.0	100.0	-	-	100.0
Skin	Male	13	7	1	2	-	-	23	
	Female	11	4	0	1	-	-	16	
	Total	(N)	24	11	1	3	-	-	39
		(%)	100.0	100.0	100.0	100.0	-	-	100.0
Small intestine	Male	-	-	-	1	-	-	1	
	Female	-	-	-	-	-	-	0	
	Total	(N)	-	-	-	1	-	-	1
		(%)	-	-	-	100	-	-	100.0
Stomach	Male	2	5	5	5	-	-	17	
	Female	0	1	5	6	-	-	12	
	Total	(N)	2	6	10	11	-	-	29
		(%)	100.0	100.0	100.0	100.0	-	-	100.0

TABLE 24

NUMBER OF NEW CANCER PATIENTS STAGE AND GENDER : 2021

Site	Sex		Stage						
			I	II	III	IV	No stage	Un known	Total
Thyroid gland	Male		5	1	6	2	-	-	14
	Female		53	16	8	2	-	-	79
	Total	(N)	58	17	14	4	-	-	93
		(%)	100.0	100.0	100.0	100.0	-	-	100.0
Tonsil	Male		-	2	2	1	-	-	5
	Female		-	0	0	1	-	-	1
	Total	(N)	-	2	2	2	-	-	6
		(%)	-	100.0	100.0	100.0	-	-	100.0
Trachea, bronchus & lung	Male		3	7	15	70	-	-	95
	Female		11	4	6	46	-	-	67
	Total	(N)	14	11	21	116	-	-	162
		(%)	100.0	100.0	100.0	100.0	-	-	100.0
Without specification of site	Male		-	1	1	2	-	0	4
	Female		-	0	0	4	-	1	5
	Total	(N)	-	1	1	6	-	1	9
		(%)	-	100	100.0	100.0	-	100	100.0
Male genital organs	Male		2	2	-	-	-	-	4
	Female		-	-	-	-	-	-	0
	Total	(N)	2	2	-	-	-	-	4
		(%)	100	100.0	-	-	-	-	100.0
Eye & Meninges	Male		-	-	-	-	1	-	1
	Female		-	-	-	-	1	-	1
	Total	(N)	-	-	-	-	2	-	2
		(%)	-	-	-	-	100.0	-	100.0



DESCRIPTION OF THE LEADING SITES OF CANCERS

1. BREAST


2. COLON & RECTUM

3. TRACHEA, BRONCHUS AND LUNG

4. LIVER AND INTRAHEPATIC BILE DUCTS

5. PROSTATE GLAND

6. NON-HODGKIN'S LYMPHOMA






1. BREAST CANCER

TABLE 25 TREND OF BREAST CANCER IN PHRAMONGKUTKLAO HOSPITAL : 2010 - 2021

Years	Number of patients		Total
	Male	Female	
2010	2	221	223
2011	0	219	219
2012	1	291	292
2013	1	285	286
2014	0	261	261
2015	2	197	199
2016	2	198	200
2017	5	166	171
2018	4	180	184
2019	3	206	209
2020	3	181	184
2021	2	210	212






BREAST CANCER

TABLE 26 DISTRIBUTION OF BREAST CANCER PATIENTS BY AGE GROUP AND GENDER : 2021

Age group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 – 29	0	0.0	1	0.5	1	0.5
30 – 34	0	0.0	3	1.4	3	1.4
35 – 39	0	0.0	12	5.7	12	5.7
40 – 44	0	0.0	22	10.5	22	10.4
45 – 49	0	0.0	16	7.6	16	7.5
50 – 54	0	0.0	28	13.3	28	13.2
55 – 59	0	0.0	38	18.2	38	17.9
60 – 64	1	50.0	33	15.7	34	16.0
65 – 69	1	50.0	20	9.5	21	9.9
70 – 74	0	0.0	16	7.6	16	7.5
75 – 79	0	0.0	7	3.4	7	3.4
80 – 84	0	0.0	11	5.2	11	5.2
85 +	0	0.0	3	1.4	3	1.4
Total	2	100.0	210	100.0	212	100.0

Majority of cases

FIGURE 15: DISTRIBUTION OF BREAST CANCER PATIENTS BY AGE GROUP AND GENDER: 2021






BREAST CANCER

Staging	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Stage I	0	0.0	68	32.4	68	32.1
Stage II	0	0.0	63	30.0	63	29.7
Stage III	0	0.0	43	20.5	43	20.3
Stage IV	2	100.0	36	17.1	38	17.9
Total	2	100.0	210	100.0	212	100.0

FIGURE 16: DISTRIBUTION OF NEW BREAST CANCER PATIENTS BY STAGE AND GENDER: 2021





BREAST CANCER


TABLE 28 DISTRIBUTION OF NEW BREAST CANCER PATIENTS BY METHOD AND GENDER : 2021

Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Radiology	0	0.0	11	5.2	11	5.2
Histopathology or Cytology	2	100.0	199	94.8	201	94.8
Total	2	100.0	210	100.0	212	100.0

TABLE 29 DISTRIBUTION OF NEW BREAST CANCER PATIENTS BY EXTENSION AND GENDER : 2021

Extension	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Localized	0	0.0	125	59.5	125	59.0
Regional lymph nodes	0	0.0	51	24.3	51	24.1
Distant metastasis	2	100.0	34	16.2	36	17.0
Total	2	100.0	210	100.0	212	100.0

FIGURE 17: DISTRIBUTION OF NEW BREAST CANCER PATIENTS BY EXTENSION AND GENDER: 2021





BREAST CANCER

TABLE 30 DISTRIBUTION OF NEW BREAST CANCER PATIENTS BY TREATMENT MODALITIES AND GENDER : 2021

Treatment modality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery	1	50.0	65	31.0	66	31.1
Radiotherapy	0	0.0	29	13.8	29	13.7
Chemotherapy	0	0.0	26	12.4	26	12.3
Hormone	0	0.0	1	0.5	1	0.5
Immunotherapy	0	0.0	1	0.5	1	0.5
Interventional	0	0.0	4	1.9	4	1.9
Surgery & Radiotherapy	0	0.0	20	9.5	20	9.4
Surgery & Chemotherapy	0	0.0	12	5.7	12	5.7
Radiotherapy & Chemotherapy	0	0.0	9	4.3	9	4.2
Surgery & Radiotherapy & Chemotherapy	1	50.0	6	2.9	7	3.3
Counseling	0	0.0	37	17.5	37	17.4
Total	2	100.0	210	100.0	212	100.0

TABLE 31 DISTRIBUTION OF NEW BREAST CANCER PATIENTS BY TREATMENT FOLLOW UP STATUS AND GENDER : 2021

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	2	100.0	192	91.4	194	91.5
Deaths	0	0.0	18	8.6	18	8.5
Total	2	100.0	210	100.0	212	100.0

Survey: 31 December 2021




2. COLON & RECTUM CANCER

TABLE 32

TREND OF COLON & RECTUM CANCER IN PHRAMONGKUTKLAO HOSPITAL:
2010 - 2021

Years	Number of patients		Total
	Male	Female	
2010	111	76	187
2011	123	78	201
2012	146	78	224
2013	131	87	218
2014	130	87	217
2015	120	81	201
2016	140	88	228
2017	102	67	169
2018	104	56	160
2019	132	91	223
2020	107	72	179
2021	117	82	199






COLON & RECTUM CANCER

TABLE 33 DISTRIBUTION OF NEW COLON & RECTUM CANCER PATIENTS BY AGE GROUP AND GENDER: 2021

Age group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 – 24	0	0.0	0	0.0	0	0.0
25 – 29	0	0.0	1	1.2	1	0.5
30 – 34	0	0.0	1	1.2	1	0.5
35 – 39	0	0.0	2	2.4	2	1.0
40 – 44	4	3.4	3	3.7	7	3.5
45 – 49	5	4.3	2	2.4	7	3.5
50 – 54	8	6.8	2	2.4	10	5.0
55 – 59	15	12.8	13	15.9	28	14.1
60 – 64	18	15.4	10	12.2	28	14.1
65 – 69	17	14.5	12	14.6	29	14.6
70 – 74	13	11.1	13	15.9	26	13.1
75 – 79	18	15.4	8	9.8	26	13.1
80 – 84	11	9.4	12	14.6	23	11.6
85 +	8	6.9	3	3.7	11	5.4
Total	117	100.0	82	100.0	199	100.0

Majority of cases

FIGURE 18: DISTRIBUTION OF NEW COLON & RECTUM CANCER PATIENTS BY AGE GROUP AND GENDER: 2021






COLON & RECTUM CANCER

TABLE34 DISTRIBUTION OF NEW COLON & RECTUM CANCER PATIENTS BY STAGE AND GENDER : 2021						
Staging	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Stage I	17	14.5	10	12.2	27	13.6
Stage II	28	23.9	22	26.8	50	25.1
Stage III	29	24.8	25	30.5	54	27.1
Stage IV	43	36.8	25	30.5	68	34.2
Total	117	100.0	82	100.0	199	100.0

FIGURE 19: DISTRIBUTION OF NEW COLON & RECTUM CANCER PATIENTS BY STAGE AND GENDER: 2021





COLON & RECTUM CANCER


TABLE 35 DISTRIBUTION OF NEW COLON & RECTUM CANCER PATIENTS BY METHOD AND GENDER : 2021

Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Radiology	2	1.7	1	1.2	3	1.5
Histopathology or Cytology	108	92.3	76	92.7	284	92.5
Endoscopy	7	6.0	5	6.1	12	6.0
Total	117	100.0	82	100.0	199	100.0

TABLE 36 DISTRIBUTION OF NEW COLON & RECTUM CANCER PATIENTS BY EXTENSION AND GENDER : 2021

Extension	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Localized	52	44.4	33	40.2	85	42.7
Regional lymph nodes	23	19.7	23	28.1	46	23.1
Distant metastasis	42	35.9	26	31.7	68	34.2
Total	117	100.0	82	100.0	199	100.0

FIGURE 20: DISTRIBUTION OF NEW COLON & RECTUM CANCER PATIENTS BY EXTENSION AND GENDER: 2021





COLON & RECTUM CANCER

TABLE 37 DISTRIBUTION OF NEW COLON & RECTUM CANCER PATIENTS BY TREATMENT MODALITIES AND GENDER : 2021

Treatment modality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery	41	35.0	24	29.3	65	32.7
Radiotherapy	8	6.8	6	7.3	14	7.0
Chemotherapy	9	7.6	13	15.9	22	11.1
Hormone	1	0.9	0	0.0	1	0.5
Immunotherapy	1	0.9	0	0.0	1	0.5
Interventional	4	3.4	5	6.1	9	4.5
Surgery & Radiotherapy	4	3.4	2	2.4	6	3.0
Surgery & Chemotherapy	27	23.1	17	20.7	44	22.1
Radiotherapy & Chemotherapy	3	2.6	3	3.7	6	3.0
Surgery & Radiotherapy & Chemotherapy	3	2.6	2	2.4	5	2.5
Counseling	16	13.7	10	12.2	26	13.1
Total	117	100.0	82	100.0	199	100.0

TABLE 38 DISTRIBUTION OF NEW COLON & RECTUM CANCER PATIENTS BY TREATMENT FOLLOW UP STATUS AND GENDER : 2021

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	92	78.6	69	84.1	161	80.9
Deaths	25	21.4	13	15.9	38	19.1
Total	117	100.0	82	100.0	199	100.0

Survey: 31 December 2021



3. TRACHEA, BRONCHUS AND LUNG CANCER

TABLE 39

TREND OF TRACHEA, BRONCHUS AND LUNG CANCER IN PHRAMONGKUTKLAO HOSPITAL: 2010 – 2021

Years	Number of patients		Total
	Male	Female	
2010	104	61	165
2011	142	68	210
2012	146	69	215
2013	145	75	220
2014	134	84	218
2015	115	65	180
2016	119	79	198
2017	118	73	191
2018	119	81	200
2019	142	70	212
2020	109	63	172
2021	95	67	162






TRACHEA, BRONCHUS AND LUNG CANCER

TABLE 40 DISTRIBUTION OF NEW TRACHEA, BRONCHUS AND LUNG CANCER PATIENTS BY AGE GROUP AND GENDER : 2021

Age group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 – 19	0	0.0	0	0.0	0	0.0
20 – 24	1	1.1	0	0.0	1	0.6
25 – 29	1	1.1	0	0.0	1	0.6
30 – 34	1	1.1	0	0.0	1	0.6
35 – 39	1	1.1	1	1.5	2	1.3
40 – 44	2	2.1	3	4.6	5	3.1
45 – 49	3	3.2	1	1.5	4	2.5
50 – 54	5	5.3	8	11.9	13	8.0
55 – 59	13	13.6	8	11.9	21	13.0
60 – 64	19	20.0	11	16.5	30	18.5
65 – 69	19	20.0	8	11.9	27	16.7
70 – 74	12	12.5	8	11.9	20	12.3
75 – 79	5	5.3	8	11.9	13	8.0
80 – 84	11	11.5	7	10.4	18	11.1
85 +	2	2.1	4	6.0	6	3.7
Total	95	100.0	67	100.0	162	100.0

Majority of cases

FIGURE 21: DISTRIBUTION OF NEW TRACHEA, BRONCHUS AND LUNG CANCER PATIENTS BY AGE GROUP AND GENDER: 2021






TRACHEA, BRONCHUS AND LUNG CANCER

TABLE 41: DISTRIBUTION OF NEW TRACHEA, BRONCHUS AND LUNG CANCER PATIENTS BY STAGE AND GENDER : 2021						
Staging	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Stage I	3	3.1	11	16.3	14	8.6
Stage II	7	7.4	4	6.0	11	6.8
Stage III	15	15.8	6	9.0	21	13.0
Stage IV	70	73.7	46	68.7	116	71.6
Total	95	100.0	67	100.0	162	100.0

FIGURE 22: DISTRIBUTION OF NEW TRACHEA, BRONCHUS AND LUNG CANCER PATIENTS BY STAGE AND GENDER: 2021





TRACHEA, BRONCHUS AND LUNG CANCER


TABLE 42 DISTRIBUTION OF NEW TRACHEA, BRONCHUS AND LUNG CANCER PATIENTS BY METHOD AND GENDER : 2021

Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Endoscopy & Radiology	2	2.1	4	6.0	6	3.7
Histopathology or Cytology	92	96.8	63	94.0	155	95.7
Endoscopy	1	1.1	0	0.0	1	0.6
Total	95	100.0	67	100.0	162	100.0

TABLE 43 DISTRIBUTION OF NEW TRACHEA, BRONCHUS AND LUNG CANCER PATIENTS BY EXTENSION AND GENDER : 2021

Extension	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Localized	17	17.9	19	28.4	36	22.2
Regional lymph nodes	16	16.8	5	7.5	21	13.0
Distant metastasis	62	65.3	43	64.1	105	64.8
Total	95	100.0	67	100.0	162	100.0

FIGURE 23: DISTRIBUTION OF NEW TRACHEA, BRONCHUS AND LUNG CANCER PATIENTS BY EXTENSION AND GENDER: 2021





TRACHEA, BRONCHUS AND LUNG CANCER

TABLE 44 DISTRIBUTION OF NEW TRACHEA, BRONCHUS AND LUNG CANCER PATIENTS BY TREATMENT MODALITIES AND GENDER : 2021

Treatment modality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery	29	30.3	18	26.7	47	29.2
Radiotherapy	8	8.4	6	9.0	14	8.6
Chemotherapy	22	23.2	14	20.9	36	22.2
Immunotherapy	1	1.1	1	1.5	2	1.2
Interventional	1	1.1	3	4.5	4	2.5
Surgery & Radiotherapy	5	5.3	3	4.5	8	4.9
Surgery & Chemotherapy	7	7.4	5	7.5	12	7.4
Radiotherapy & Chemotherapy	3	3.2	4	6.0	7	4.3
Surgery & Radiotherapy & Chemotherapy	4	4.2	3	4.5	7	4.3
Counseling	15	15.8	10	14.9	25	15.4
Total	95	100.0	67	100.0	162	100.0

TABLE 45 DISTRIBUTION OF NEW TRACHEA, BRONCHUS AND LUNG CANCER PATIENTS BY TREATMENT FOLLOW UP STATUS AND GENDER : 2021

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	48	50.5	47	70.1	95	58.6
Deaths	47	49.5	20	29.9	67	41.4
Total	95	100.0	67	100.0	162	100.0

Survey: 31 December 2021



4. LIVER AND INTRAHEPATIC BILE DUCTS CANCER


TABLE 46

DISTRIBUTION OF NEW LIVER AND INTRAHEPATIC BILE DUCTS CANCER PATIENTS BY AGE GROUP AND GENDER : 2021

Age group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 – 29	0	0.0	0	0.0	0	0.0
30 – 34	1	1.2	1	5.0	2	1.9
35 – 39	3	3.6	0	0.0	3	2.9
40 – 44	3	3.6	3	15.0	6	5.7
45 – 49	4	4.8	1	5.0	5	4.9
50 – 54	10	12.1	1	5.0	11	10.6
55 – 59	12	14.5	0	0.0	12	11.7
60 – 64	15	18.1	3	15.0	18	17.5
65 – 69	14	16.9	4	20.0	18	17.5
70 – 74	8	9.6	4	20.0	12	11.7
75 – 79	4	4.8	2	10.0	6	5.8
80 – 84	4	4.8	1	5.0	5	4.9
85 +	5	6.0	0	0.0	5	4.9
Total	83	100.0	20	100.0	103	100.0

Majority of cases

FIGURE 24: DISTRIBUTION OF NEW LIVER AND INTRAHEPATIC BILE DUCTS CANCER PATIENTS BY AGE GROUP AND GENDER: 2021







LIVER AND INTRAHEPATIC BILE DUCTS CANCER

TABLE 47 DISTRIBUTION OF NEW LIVER AND INTRAHEPATIC BILE DUCTS CANCER PATIENTS BY STAGE AND GENDER : 2021

Staging	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Stage I	10	12.0	0	0.0	10	9.7
Stage II	26	31.3	5	25.0	31	30.1
Stage III	23	27.8	2	10.0	25	24.3
Stage IV	24	28.9	13	65.0	37	35.9
Total	83	100.0	20	100.0	103	100.0

FIGURE 25: DISTRIBUTION OF NEW LIVER AND INTRAHEPATIC BILE DUCTS CANCER PATIENTS BY STAGE AND GENDER: 2021





LIVER AND INTRAHEPATIC BILE DUCTS CANCER


TABLE 48 DISTRIBUTION OF LIVER AND INTRAHEPATIC BILE DUCTS CANCER PATIENTS BY METHOD AND GENDER : 2021

Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Radiology	4	4.8	0	0.0	4	3.9
Histopathology or Cytology	30	36.1	9	45.0	39	37.9
Tumor marker	49	59.1	11	55.0	60	58.2
Total	83	100.0	20	100.0	103	100.0

TABLE 49 DISTRIBUTION OF LIVER AND INTRAHEPATIC BILE DUCTS CANCER PATIENTS BY EXTENSION AND GENDER : 2021

Extension	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Localized	62	74.7	10	50.0	72	69.9
Distant metastasis	21	25.3	10	50.0	31	30.1
Total	83	100.0	20	100.0	103	100.0

FIGURE 26: DISTRIBUTION OF NEW LIVER AND INTRAHEPATIC BILE DUCTS CANCER PATIENTS BY EXTENSION AND GENDER: 2021





LIVER AND INTRAHEPATIC BILE DUCTS CANCER

TABLE 50

DISTRIBUTION OF NEW LIVER AND INTRAHEPATIC BILE DUCTS CANCER PATIENTS BY TREATMENT MODALITIES AND GENDER : 2021

Treatment modality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery	15	18.1	4	20.0	19	18.4
Radiotherapy	4	4.8	4	20.0	8	7.8
Chemotherapy	20	24.1	0	0.0	20	19.4
Immunotherapy	1	1.2	0	0.0	1	1.0
Interventional	15	18.1	6	30.0	21	20.4
Surgery & Radiotherapy	3	3.6	0	0.0	3	2.9
Surgery & Chemotherapy	6	7.2	3	15.0	9	8.7
Radiotherapy & Chemotherapy	3	3.6	2	10.0	5	4.9
Surgery & Radiotherapy & Chemotherapy	1	1.2	0	0.0	1	1.0
Counseling	15	18.1	1	5.0	16	15.5
Total	83	100.0	20	100.0	103	100.0

TABLE 51

DISTRIBUTION OF NEW LIVER AND INTRAHEPATIC BILE DUCTS CANCER PATIENTS BY FOLLOW UP STATUS AND GENDER : 2021

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	43	51.8	7	35.0	50	48.5
Deaths	40	48.2	13	65.0	53	51.5
Total	83	100.0	20	100.0	103	100.0

Survey: 31 December 2021



5. PROSTATE GLAND CANCER


TABLE 52

DISTRIBUTION OF NEW PROSTATE GLAND CANCER PATIENTS BY AGE GROUP AND GENDER : 2021

Age group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 – 44	0	0.0	0	0.0	0	0.0
45 – 49	0	0.0	0	0.0	0	0.0
50 – 54	2	2.1	0	0.0	2	2.1
55 – 59	4	4.1	0	0.0	4	4.1
60 – 64	10	10.3	0	0.0	10	10.3
65 – 69	23	23.7	0	0.0	23	23.7
70 – 74	31	32.0	0	0.0	31	32.0
75 – 79	9	9.3	0	0.0	9	9.3
80 – 84	13	13.3	0	0.0	13	13.3
85 +	5	5.2	0	0.0	5	5.2
Total	97	100.0	0	0.0	97	100.0

Majority of cases

FIGURE 27: DISTRIBUTION OF NEW PROSTATE GLAND CANCER PATIENTS BY AGE GROUP AND GENDER: 2021







PROSTATE GLAND CANCER

TABLE 53 DISTRIBUTION OF NEW PROSTATE GLAND CANCER PATIENTS BY STAGE AND GENDER : 2021						
Staging	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Stage I	25	25.8	0	0.0	25	25.8
Stage II	35	36.1	0	0.0	35	36.1
Stage III	12	12.3	0	0.0	12	12.3
Stage IV	25	25.8	0	0.0	25	25.8
Total	97	100.0	0	0.0	97	100.0

FIGURE 28: DISTRIBUTION OF NEW PROSTATE GLAND CANCER PATIENTS BY STAGE AND GENDER: 2021





PROSTATE GLAND CANCER


TABLE 54 DISTRIBUTION OF NEW PROSTATE GLAND CANCER PATIENTS BY METHOD AND GENDER : 2021

Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Endoscopy & Radiology	2	2.1	0	0.0	2	2.1
Histopathology or Cytology	95	97.9	0	0.0	95	97.9
Total	97	100.0	0	0.0	97	100.0

TABLE 55 DISTRIBUTION OF NEW PROSTATE GLAND CANCER PATIENTS BY EXTENSION AND GENDER : 2021

Extension	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Localized	71	73.2	0	0.0	71	73.2
Regional lymph nodes	8	8.2	0	0.0	8	8.2
Distant metastasis	18	18.6	0	0.0	18	18.6
Total	97	100.0	0	0.0	97	100.0

FIGURE 29: DISTRIBUTION OF NEW PROSTATE GLAND CANCER PATIENTS BY EXTENSION AND GENDER: 2021





PROSTATE GLAND CANCER

TABLE 56 DISTRIBUTION OF NEW PROSTATE GLAND CANCER PATIENTS BY TREATMENT MODALITIES AND GENDER : 2021

Treatment modality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery	38	39.2	0	0.0	38	39.2
Radiotherapy	17	17.5	0	0.0	17	17.5
Chemotherapy	5	5.2	0	0.0	5	5.2
Immunotherapy	1	1.0	0	0.0	1	1.0
Interventional	1	1.0	0	0.0	1	1.0
Surgery & Radiotherapy	7	7.2	0	0.0	7	7.2
Surgery & Chemotherapy	5	5.2	0	0.0	5	5.2
Radiotherapy & Chemotherapy	2	2.1	0	0.0	2	2.1
Surgery & Radiotherapy & Chemotherapy	2	2.1	0	0.0	2	2.1
Counseling	19	19.5	0	0.0	19	19.5
Total	97	100.0	0	0.0	97	100.0

TABLE 57 DISTRIBUTION OF NEW PROSTATE GLAND CANCER PATIENTS BY FOLLOW UP STATUS AND GENDER : 2021

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	91	93.8	0	0.0	91	93.8
Deaths	6	6.2	0	0.0	6	6.2
Total	97	100.0	0	0.0	97	100.0

Survey: 31 December 2021



6. NON-HODGKIN'S LYMPHOMA CANCER


TABLE 58

DISTRIBUTION OF NEW NON-HODGKIN'S LYMPHOMA CANCER PATIENTS BY AGE GROUP IN MALE : 2021

Age group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 – 09	0	0.0	2	3.9	2	2.1
10 – 14	1	2.2	0	0.0	1	1.0
15 – 19	0	0.0	0	0.0	0	0.0
20 – 24	0	0.0	0	0.0	0	0.0
25 – 29	4	8.9	1	2.0	5	5.2
30 – 34	2	4.4	3	5.9	5	5.2
35 – 39	1	2.2	3	5.9	4	4.2
40 – 44	0	0.0	3	5.9	3	3.1
45 – 49	3	6.7	0	0.0	3	3.1
50 – 54	6	13.3	3	5.9	9	9.4
55 – 59	5	11.1	6	11.8	11	11.5
60 – 64	8	17.8	7	13.7	15	15.6
65 – 69	3	6.7	9	17.6	12	12.5
70 – 74	4	8.9	2	3.9	6	6.3
75 – 79	2	4.4	8	15.7	10	10.4
80 – 84	3	6.7	3	5.9	6	6.3
85 +	3	6.7	1	2.0	4	4.2
Total	45	100.0	51	100.0	96	100.0

Majority of cases

FIGURE 30: DISTRIBUTION OF NEW NON-HODGKIN'S LYMPHOMA CANCER PATIENTS BY AGE GROUP IN MALE: 2021






NON-HODGKIN'S LYMPHOMA CANCER

TABLE 59 DISTRIBUTION OF NEW NON-HODGKIN'S LYMPHOMA CANCER PATIENTS BY STAGE IN MALE: 2021						
Staging	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Stage I	9	20.0	10	19.6	19	19.8
Stage II	6	13.3	12	23.5	18	18.8
Stage III	7	15.6	11	21.6	18	18.8
Stage IV	14	31.1	15	29.4	29	30.2
No stage	9	20.0	3	5.9	12	12.5
Total	45	100.0	51	100.0	96	100.0

FIGURE 31: DISTRIBUTION OF NEW NON-HODGKIN'S LYMPHOMA CANCER PATIENTS BY STAGE IN MALE: 2021






NON-HODGKIN'S LYMPHOMA CANCER

TABLE 60 DISTRIBUTION OF NEW NON-HODGKIN'S LYMPHOMA CANCER PATIENTS BY METHOD IN MALE : 2021						
Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Histopathology or Cytology	10	22.2	7	13.7	17	17.7
Bone marrow examination	35	77.8	44	86.3	79	82.3
Total	45	100.0	51	100.0	96	100.0

TABLE 61 DISTRIBUTION OF NEW NON-HODGKIN'S LYMPHOMA CANCER PATIENTS BY EXTENSION IN MALE : 2021						
Extension	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Localized	36	80.0	43	84.3	79	82.3
Regional lymph nodes	1	2.2	1	2.0	2	2.1
Distant metastasis	8	17.8	7	13.7	15	15.6
Total	45	100.0	51	100.0	96	100.0

FIGURE 32: DISTRIBUTION OF NEW NON-HODGKIN'S LYMPHOMA CANCER PATIENTS BY EXTENSION IN MALE: 2021





NON-HODGKIN'S LYMPHOMA CANCER

TABLE 62

DISTRIBUTION OF NEW NON-HODGKIN'S LYMPHOMA CANCER PATIENTS BY TREATMENT MODALITIES IN MALE: 2021

Treatment modality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery	8	17.8	5	9.8	13	13.5
Radiotherapy	5	11.2	3	5.9	8	8.3
Chemotherapy	11	24.4	12	23.5	23	24.0
Immunotherapy	1	2.2	4	7.8	5	5.2
Interventional	2	4.4	1	2.0	3	3.1
Surgery & Radiotherapy	3	6.7	5	9.8	8	8.3
Surgery & Chemotherapy	3	6.7	3	5.9	6	6.3
Radiotherapy & Chemotherapy	2	4.4	4	7.8	6	6.3
Surgery & Radiotherapy & Chemotherapy	1	2.2	1	2.0	2	2.1
Counseling	9	20.0	13	25.5	22	22.9
Total	45	100.0	51	100.0	96	100.0

TABLE 63

DISTRIBUTION OF NEW NON-HODGKIN'S LYMPHOMA CANCER PATIENTS BY FOLLOW UP STATUS IN MALE: 2021

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	36	80.0	43	84.3	79	82.3
Deaths	9	20.0	8	15.7	17	17.7
Total	45	100.0	51	100.0	96	100.0

Survey: 31 December 2021

2021 HOSPITAL-BASED CANCER REGISTRY ANNUAL REPORT



● MALE ●

TABLE 64 DISTRIBUTION OF NEW CANCER IN MALE BY AGE - GROUP : 2021

ICD_10	Site	Age	0	5	10	15	20	25	30	35	40	45	50	55	60	65	70	75	80	85	
			-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		Total	4	9	14	19	24	29	34	39	44	49	54	59	64	69	74	79	84		
C00-C08	Oral cavity	19	0	0	0	0	0	0	0	1	1	3	2	7	0	2	3	0	0	0	
C01,C05,C10	Oropharynx	3	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	1	
C09	Tonsil	5	0	0	0	0	0	0	0	0	1	0	0	1	2	1	0	0	0	0	
C11	Nasopharynx	8	0	0	0	0	2	0	0	0	0	2	1	1	1	1	0	0	0	0	
C12-C13	Hypopharynx	11	0	0	0	0	0	0	0	0	1	3	1	1	1	4	0	0	0	0	
C14	Pharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
C15	Esophagus	27	0	0	0	0	0	0	0	0	0	2	4	3	8	4	4	1	0	1	
C16	Stomach	17	0	0	0	0	0	0	0	1	0	2	0	1	5	2	2	1	2	1	
C17	Small intestine	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	
C18-C20	Colon and Rectum	117	0	0	0	0	0	0	0	0	4	5	8	15	18	17	13	18	11	8	
C21	Anus	5	0	0	0	0	0	0	0	1	1	0	0	0	0	1	1	1	0	0	
C22	Liver and Bile ducts	83	0	0	0	0	0	0	1	3	3	4	10	12	15	14	8	4	4	5	
C23-C24	Gallbladder	7	0	0	0	0	0	0	0	0	0	0	0	2	0	1	2	1	0	1	
C25	Pancreas	18	0	0	0	0	0	0	0	1	0	1	1	3	1	3	3	0	4	1	
C30-C31	Nose, sinuses etc	7	0	1	0	0	0	0	0	2	0	1	1	1	0	0	0	0	0	1	
C32	Larynx	14	0	0	0	0	0	0	0	0	1	0	2	2	1	4	0	1	1	2	
C33-C34	Trachea, bronchus, lung	95	0	0	0	0	1	1	1	1	2	3	5	13	19	19	12	5	11	2	
C37-C39	Other thoracic organs	9	0	0	1	1	0	1	0	0	0	0	1	2	3	0	0	0	0	0	
C40-C41	Bone & joints	6	0	0	0	1	0	1	0	1	0	0	0	2	0	1	0	0	0	0	
C43-C44	Melanoma of skin	23	0	0	0	0	1	0	0	0	0	1	0	4	0	4	5	2	2	4	
C45-C49	Mesothelioma	21	0	0	0	0	0	2	1	0	2	3	1	2	1	5	1	0	2	1	
C50	Breast	2	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	
C60, C62-C63	Male genital organs	4	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	1	0	
C61	Prostate	97	0	0	0	0	0	0	0	0	0	0	2	4	10	23	31	9	13	5	
C64-C66	Kidney & Ureter	24	0	0	0	0	0	0	0	1	1	1	1	3	4	5	3	4	1	0	
C67	Bladder	21	0	0	0	0	0	0	0	0	0	0	0	3	3	4	3	4	2	2	
C69-C70	Eye & Meninges	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	
C71-C72	Brain	8	0	0	1	0	1	0	0	1	0	0	1	1	0	1	1	1	0	0	
C73	Thyroid gland	14	0	0	0	0	1	2	0	0	2	1	2	0	4	0	1	0	0	1	
C74	Adrenal gland	2	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	
C75	Other endocrine glands	6	0	0	0	0	0	0	0	0	0	0	1	1	1	0	1	0	0	2	
C80	Without unspecified	4	0	0	0	0	1	0	0	1	0	0	0	0	0	1	0	1	0	0	
C81	Hodgkin's disease	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	
C82 -C85,	Non-Hodgkin lymphoma	45	0	0	1	0	0	4	2	1	0	3	6	5	8	3	4	2	3	3	
C90	Multiple myeloma	17	0	0	0	0	0	0	0	0	0	2	3	4	1	4	3	0	0	0	
C91-C95	Leukemia	29	3	0	0	1	3	0	2	1	1	1	0	4	4	4	3	1	1	0	
Total		771	3	1	3	3	13	12	8	17	20	38	53	97	111	130	105	57	59	41	



● FEMALE ●

TABLE 65 DISTRIBUTION OF NEW CANCER IN MALE BY AGE - GROUP : 2021

ICD_10	Site	Age	0	5	10	15	20	25	30	35	40	45	50	55	60	65	70	75	80	85		
			-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
			Total	4	9	14	19	24	29	34	39	44	49	54	59	64	69	74	79	84		
C00-C08	Oral cavity	10	0	0	0	0	0	0	0	0	1	1	0	2	1	1	1	1	1	1		
C01,C05,C10	Oropharynx	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0		
C11	Nasopharynx	3	0	0	0	0	0	0	0	0	0	0	0	3	0	0	0	0	0	0		
C09	Tonsil	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0		
C16	Stomach	12	0	0	0	0	0	0	0	0	1	1	0	1	2	3	0	2	2	0		
C17	Small intestine	3	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	1	0		
C18-C20	Colon and Rectum	82	0	0	0	0	0	1	1	2	3	2	2	13	10	12	13	8	12	3		
C21	Anus	6	0	0	0	0	0	0	0	0	0	0	0	2	1	1	2	0	0	0		
C22	Liver and Bile ducts	20	0	0	0	0	0	0	1	0	3	1	1	0	3	4	4	2	1	0		
C23-C24	Gallbladder	2	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0		
C25	Pancreas	8	0	0	0	0	0	0	0	1	0	0	1	0	1	2	2	1	0	0		
C26	Other and ill-defined digestive organs	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0		
C30-C31	Nose, sinuses etc	3	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	1	0		
C32	Larynx	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0		
C33-C34	Trachea, bronchus, lung	67	0	0	0	0	0	0	0	1	3	1	8	8	11	8	8	8	7	4		
C37-C39	Other thoracic organs	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0		
C40-C41	Bone	7	0	0	1	0	3	0	0	0	3	0	0	0	0	0	0	0	0	0		
C43-C44	Melanoma of skin	16	0	0	0	0	0	0	0	1	0	0	1	2	2	0	3	2	2	3		
C45-C49	Connective and soft tissue	15	0	0	0	0	0	1	0	1	1	2	0	2	1	5	1	0	1	0		
C50	Breast	210	0	0	0	0	1	0	3	12	22	16	28	38	33	20	16	7	11	3		
C51-C52, C57	Female genital organs	6	0	0	0	0	0	0	0	0	0	2	0	0	2	2	0	0	0	0		
C53	Cervix uteri	23	0	0	0	0	0	1	1	1	3	3	1	5	3	1	2	2	0	0		
C54	Corpus uteri	41	0	0	0	0	0	0	1	2	0	3	1	12	6	9	3	2	1	1		
C55	Uterus	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0		
C56	Ovary	23	0	0	0	0	1	1	1	1	1	5	5	1	2	2	1	0	2	0		
C64-C66	Kidney & Ureter	10	0	1	0	0	0	1	0	0	0	0	1	1	1	2	0	2	1	0		
C67	Bladder	4	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0	0	0	1		
C69-C70	Eye & Meninges	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0		
C71-C72	Brain	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0		
C73	Thyroid gland	79	0	0	0	0	5	11	4	9	7	7	14	9	6	3	3	1	0	0		
C78	other endocrine glands and relate structures	5	0	0	0	0	0	0	0	0	0	0	1	1	2	0	0	1	0	0		
C80	Without unspecified	5	0	0	0	0	1	0	3	0	0	0	0	0	1	0	0	0	0	0		
C81	Hodgkin's disease	51	2	0	0	0	0	1	3	3	3	0	3	6	7	9	2	8	3	1		
C82 - C85	Non-Hodgkin lymphoma	12	0	0	0	0	0	0	0	1	2	1	1	2	1	0	4	0	0	0		
C90	Multiple myeloma	21	2	1	1	0	0	1	0	1	2	2	0	1	1	4	1	1	3	0		
C91-C95	Leukaemia	3	0	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0	0		
Total		755	4	2	2	0	11	19	18	37	55	49	69	113	101	92	68	48	50	17		



TABLE 66 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2021

ICD-10	Code	Morphology Description	Number of cases		
			Male	Female	Total
C00-C08	Lip & Oral cavity		18	11	29
C004	8070/3	Squamous cell carcinoma, NOS	0	1	1
C009	8070/3	Squamous cell carcinoma, NOS	0	1	1
	8071/3	Squamous cell carcinoma, keratinizing, NOS	1	0	1
C01	8070/3	Squamous cell carcinoma, NOS	3	0	3
	8070/6	Squamous cell carcinoma, metastatic, NOS	1	0	1
C020	8070/3	Squamous cell carcinoma, NOS	2	3	5
	8071/3	Squamous cell carcinoma, keratinizing, NOS	1	0	1
C021	8070/3	Squamous cell carcinoma, NOS	1	0	1
C029	8070/3	Squamous cell carcinoma, NOS	1	1	2
C049	8010/3	Carcinoma, NOS	1	0	1
	8070/3	Squamous cell carcinoma, NOS	1	0	1
C050	8070/3	Squamous cell carcinoma, NOS	0	1	1
	8070/3	Squamous cell carcinoma, NOS	0	1	1
C051	8070/3	Squamous cell carcinoma, NOS	1	0	1
	8070/3	Squamous cell carcinoma, NOS	1	0	1
C07	8010/3	Carcinoma, NOS	0	2	2
	8070/3	Squamous cell carcinoma, NOS	1	0	1
	8140/3	Adenocarcinoma, NOS	1	0	1
	8561/3	Epithelial-myoeithelial carcinoma	1	0	1
C080	8010/3	Carcinoma, NOS	0	1	1
C089	8200/3	Adenoid cystic carcinoma	1	0	1
C09	Tonsil		4	1	5
C090	8070/3	Squamous cell carcinoma, NOS	1	0	1
	8071/3	Squamous cell carcinoma, keratinizing, NOS	1	0	1
C091	8070/3	Squamous cell carcinoma, NOS	1	0	1
C099	8070/6	Squamous cell carcinoma, metastatic, NOS	0	1	1
	8071/3	Squamous cell carcinoma, keratinizing, NOS	1	0	1
C01, C05, C10	Oropharynx etc.		3	1	4
C101	8070/3	Squamous cell carcinoma, NOS	1	0	1
C109	8010/3	Carcinoma, NOS	1	0	1
	8070/3	Squamous cell carcinoma, NOS	1	0	1
	8090/3	Basal cell carcinoma, NOS	0	1	1
C11	Nasopharynx		7	3	10
C11	8071/3	Squamous cell carcinoma, keratinizing, NOS	1	0	1
C110	8070/3	Squamous cell carcinoma, NOS	1	0	1
C119	8010/3	Carcinoma, NOS	2	0	2
	8070/3	Squamous cell carcinoma, NOS	1	2	3
	8071/3	Squamous cell carcinoma, keratinizing, NOS	1	0	1
	8072/3	Squamous cell carcinoma, large cell, non-keratinizing, NOS	1	0	1
	8073/3	Squamous cell carcinoma, small cell, non-keratinizing, NOS	0	1	1



TABLE 66 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2021

ICD-10	Code	Morphology Description	Number of cases		
			Male	Female	Total
C12	Pyriform sinus		2	0	2
C12	8073/3	Squamous cell carcinoma, small cell, non-keratinizing, NOS	1	0	1
	8073/3	Squamous cell carcinoma, small cell, non-keratinizing, NOS	1	0	1
C13	Hypopharynx		11	0	11
C130	8070/3	Squamous cell carcinoma, NOS	2	0	2
	8070/6	Squamous cell carcinoma, metastatic, NOS	1	0	1
C131	8070/6	Squamous cell carcinoma, metastatic, NOS	1	0	1
	8070/6	Squamous cell carcinoma, metastatic, NOS	1	0	1
C139	8010/3	Carcinoma, NOS	1	0	1
	8070/3	Squamous cell carcinoma, NOS	4	0	4
	8070/6	Squamous cell carcinoma, metastatic, NOS	1	0	1
C15	Esophagus		26	3	29
C150	8070/3	Squamous cell carcinoma, NOS	1	0	1
	8070/6	Squamous cell carcinoma, metastatic, NOS	1	0	1
C151	8010/3	Carcinoma, NOS	1	0	1
	8010/6	Carcinoma, metastatic, NOS	1	0	1
	8070/3	Squamous cell carcinoma, NOS	2	0	2
C152	8070/3	Squamous cell carcinoma, NOS	0	1	1
C153	8070/3	Squamous cell carcinoma, NOS	0	1	1
	8070/6	Squamous cell carcinoma, metastatic, NOS	2	0	2
C154	8070/3	Squamous cell carcinoma, NOS	1	0	1
	8070/6	Squamous cell carcinoma, metastatic, NOS	1	0	1
C155	8070/6	Squamous cell carcinoma, metastatic, NOS	2	0	2
	8071/3	Squamous cell carcinoma, keratinizing, NOS	1	0	1
C159	8010/3	Carcinoma, NOS	2	0	2
	8070/3	Squamous cell carcinoma, NOS	5	0	5
	8070/6	Squamous cell carcinoma, metastatic, NOS	5	0	5
	8140/3	Adenocarcinoma, NOS	1	1	2
C16	Stomach		15	12	27
C16	8140/3	Adenocarcinoma, NOS	0	1	1
C160	8140/3	Adenocarcinoma, NOS	1	0	1
	8336/3	Hyalinizing trabecular adenoma	1	0	1
C162	8010/3	Carcinoma, NOS	0	1	1
	8140/3	Adenocarcinoma, NOS	4	3	7
	8336/3	Hyalinizing trabecular adenoma	1	0	1
C163	8140/3	Adenocarcinoma, NOS	1	0	1
C169	8010/3	Carcinoma, NOS	1	0	1
	8010/6	Carcinoma, metastatic, NOS	1	2	3
	8140/3	Adenocarcinoma, NOS	2	4	6
	8140/6	Adenocarcinoma, metastatic, NOS	3	1	4
C17	Small intestine		1	0	1
C170	8140/6	Adenocarcinoma, metastatic, NOS	1	0	1



TABLE 66 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2021

ICD-10	Code	Morphology Description	Number of cases		
			Male	Female	Total
C18-C20	Colon & Rectum		107	74	181
C180	8140/3	Adenocarcinoma, NOS	2	3	5
	8140/6	Adenocarcinoma, metastatic, NOS	0	3	3
C182	8140/3	Adenocarcinoma, NOS	4	4	8
	8140/6	Adenocarcinoma, metastatic, NOS	4	4	8
C183	8140/3	Adenocarcinoma, NOS	2	2	4
	8140/6	Adenocarcinoma, metastatic, NOS	1	2	3
C184	8140/3	Adenocarcinoma, NOS	1	0	1
	8140/3	Adenocarcinoma, NOS	4	1	5
	8140/6	Adenocarcinoma, metastatic, NOS	5	0	5
C185	8140/3	Adenocarcinoma, NOS	3	3	6
	8140/6	Adenocarcinoma, metastatic, NOS	1	0	1
C186	8140/3	Adenocarcinoma, NOS	5	2	7
	8140/6	Adenocarcinoma, metastatic, NOS	1	0	1
C187	8140/3	Adenocarcinoma, NOS	1	0	1
	8140/3	Adenocarcinoma, NOS	24	19	43
	8140/6	Adenocarcinoma, metastatic, NOS	10	4	14
C188	8140/3	Adenocarcinoma, NOS	2	0	2
C189	8140/3	Adenocarcinoma, NOS	5	2	7
	8140/6	Adenocarcinoma, metastatic, NOS	7	4	11
C19	8140/3	Adenocarcinoma, NOS	0	2	2
	8140/6	Adenocarcinoma, metastatic, NOS	1	0	1
C20	8010/3	Carcinoma, NOS	0	1	1
	8140/3	Adenocarcinoma, NOS	17	13	30
	8140/6	Adenocarcinoma, metastatic, NOS	7	5	12
C21	Anus & Anus canal		5	5	10
C210	8140/3	Adenocarcinoma, NOS	0	1	1
C211	8140/3	Adenocarcinoma, NOS	0	1	1
	8140/6	Adenocarcinoma, metastatic, NOS	1	0	1
C218	8010/3	Carcinoma, NOS	2	0	2
	8070/3	Squamous cell carcinoma, NOS	1	0	1
	8140/3	Adenocarcinoma, NOS	0	3	3
	8140/6	Adenocarcinoma, metastatic, NOS	1	0	1
C22	Liver & Intrahepatic bile ducts		37	11	48
C220	8010/3	Carcinoma, NOS	2	1	3
	8010/6	Carcinoma, metastatic, NOS	5	0	5
	8140/3	Adenocarcinoma, NOS	1	0	1
	8140/6	Adenocarcinoma, metastatic, NOS	2	0	2
	8170/3	Hepatocellular carcinoma, NOS	14	2	16
	8170/6	Hepatocellular carcinoma, metastatic, NOS	3	0	3





TABLE 66 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2021

ICD-10	Code	Morphology Description	Number of cases		
			Male	Female	Total
C221	8140/3	Adenocarcinoma, NOS	2	2	4
	8140/6	Adenocarcinoma, metastatic, NOS	1	2	3
	8160/3	Bile duct adenoma	1	1	2
	8170/6	Hepatocellular carcinoma, metastatic, NOS	0	1	1
C227	8140/6	Adenocarcinoma, metastatic, NOS	0	1	1
	8140/6	Adenocarcinoma, metastatic, NOS	0	1	1
C229	8170/3	Hepatocellular carcinoma, NOS	3	0	3
	8170/3	Hepatocellular carcinoma, NOS	3	0	3
C23-C24	Gall bladder & Unspecified parts of biliary tract		3	2	5
C23	8140/3	Adenocarcinoma, NOS	0	2	2
C241	8140/3	Adenocarcinoma, NOS	2	0	2
	8140/3	Adenocarcinoma, NOS	1	0	1
C25	Pancreas		12	7	19
C250	8140/3	Adenocarcinoma, NOS	1	2	3
	8140/6	Adenocarcinoma, metastatic, NOS	1	1	2
C251	8140/3	Adenocarcinoma, NOS	2	0	2
	8140/6	Adenocarcinoma, metastatic, NOS	1	1	2
C253	8010/3	Carcinoma, NOS	1	0	1
	8140/3	Adenocarcinoma, NOS	2	0	2
C259	8140/3	Adenocarcinoma, NOS	0	2	2
	8140/6	Adenocarcinoma, metastatic, NOS	3	1	4
	8560/3	Aden squamous carcinoma	1	0	1
C30-C31	Nasal cavity & Accessory sinuses		5	3	8
C300	8010/3	Carcinoma, NOS	3	1	4
	8073/3	Squamous cell carcinoma, small cell, non-keratinizing, NOS	1	0	1
	9220/3	Chondrosarcoma, NOS	1	0	1
C310	8010/3	Carcinoma, NOS	0	1	1
	8070/3	Squamous cell carcinoma, NOS	0	1	1
C32	Larynx		12	1	13
C320	8070/3	Squamous cell carcinoma, NOS	7	0	7
	8070/6	Squamous cell carcinoma, metastatic, NOS	1	0	1
	8071/3	Squamous cell carcinoma, keratinizing, NOS	0	1	1
C321	8070/3	Squamous cell carcinoma, NOS	4	0	4
C33-C34	Trachea, Bronchus & Lung		82	60	142
C340	8010/3	Carcinoma, NOS	3	0	3
	8010/6	Carcinoma, metastatic, NOS	3	2	5
	8046/3	Non-small cell carcinoma	7	3	10
	8046/6	Non-small cell carcinoma, metastatic, NOS	3	1	4
	8140/3	Adenocarcinoma, NOS	2	4	6
	8140/6	Adenocarcinoma, metastatic, NOS	3	3	6






TABLE 66 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2021

ICD-10	Code	Morphology Description	Number of cases		
			Male	Female	Total
	8801/3	Spindle cell sarcoma	0	1	1
C341	8010/6	Carcinoma, metastatic, NOS	2	0	2
	8046/3	Non-small cell carcinoma	1	1	2
	8046/6	Non-small cell carcinoma, metastatic, NOS	1	0	1
	8140/3	Adenocarcinoma, NOS	2	4	6
	8140/6	Adenocarcinoma, metastatic, NOS	1	3	4
C342	8140/3	Adenocarcinoma, NOS	1	1	2
	8140/6	Adenocarcinoma, metastatic, NOS	1	2	3
C343	8046/6	Non-small cell carcinoma, metastatic, NOS	1	0	1
	8070/6	Squamous cell carcinoma, metastatic, NOS	1	0	1
	8140/3	Adenocarcinoma, NOS	0	3	3
	8140/6	Adenocarcinoma, metastatic, NOS	1	5	6
C349	8010/3	Carcinoma, NOS	2	2	4
	8010/6	Carcinoma, metastatic, NOS	8	3	11
	8042/3	Oat cell carcinoma	1	0	1
	8046/3	Non-small cell carcinoma	4	1	5
	8046/6	Non-small cell carcinoma, metastatic, NOS	5	3	8
	8046/3	Non-small cell carcinoma	1	0	1
	8070/3	Squamous cell carcinoma, NOS	1	0	1
	8070/6	Squamous cell carcinoma, metastatic, NOS	4	1	5
	8140/3	Adenocarcinoma, NOS	3	5	8
	8140/6	Adenocarcinoma, metastatic, NOS	19	12	31
	9040/6	Synovial sarcoma, metastatic, NOS	1	0	1
C37-C38	Intrathoracic organs		7	1	8
C37	8585/3	Thymoma, type B3, malignant	1	1	2
C381	9061/3	Seminoma	1	0	1
	9064/3	Germinoma	1	0	1
C383	8032/3	Spindle cell carcinoma, NOS	1	0	1
	9085/3	Mixed germ cell tumor	1	0	1
C384	8046/6	Non-small cell carcinoma, metastatic, NOS	1	0	1
	8140/3	Adenocarcinoma, NOS	1	0	1
C40-C41	Bone & Articular cartilage		4	7	11
C401	8801/3	Spindle cell sarcoma	0	1	1
	9180/3	Osteosarcoma, NOS	0	1	1
	9220/3	Chondrosarcoma, NOS	0	1	1
C402	8140/6	Adenocarcinoma, metastatic, NOS	0	1	1
	8852/3	Myxoid lip sarcoma	1	0	1
	9180/3	Osteosarcoma, NOS	1	2	3
C414	8801/3	Spindle cell sarcoma	1	0	1
	9180/6	Osteosarcoma, metastatic, NOS	0	1	1
C419	9220/3	Chondrosarcoma, NOS	1	0	1



TABLE 66 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2021

ICD-10	Code	Morphology Description	Number of cases		
			Male	Female	Total
C43-C44	Skin		22	14	36
C43	8720/3	Malignant melanoma, NOS	0	1	1
C433	8720/3	Malignant melanoma, NOS	0	1	1
C436	8720/3	Malignant melanoma, NOS	1	0	1
C437	8723/3	Malignant melanoma, regressing	0	1	1
C439	8720/3	Malignant melanoma, NOS	1	1	2
C442	8070/3	Squamous cell carcinoma, NOS	1	0	1
	8090/3	Basal cell carcinoma, NOS	1	0	1
C443	8070/3	Squamous cell carcinoma, NOS	2	2	4
	8070/6	Squamous cell carcinoma, metastatic, NOS	1	0	1
	8090/3	Basal cell carcinoma, NOS	4	3	7
C444	8090/3	Basal cell carcinoma, NOS	1	0	1
C445	8090/3	Basal cell carcinoma, NOS	1	0	1
C446	8073/3	Squamous cell carcinoma, small cell, non-keratinizing, NOS	0	1	1
C447	8070/3	Squamous cell carcinoma, NOS	1	1	2
	8090/3	Basal cell carcinoma, NOS	1	0	1
	8720/3	Malignant melanoma, NOS	1	0	1
C448	8070/3	Squamous cell carcinoma, NOS	1	0	1
C449	8010/3	Carcinoma, NOS	1	0	1
	8070/3	Squamous cell carcinoma, NOS	1	0	1
	8071/3	Squamous cell carcinoma, keratinizing, NOS	1	0	1
	8090/3	Basal cell carcinoma, NOS	2	3	5
C45 – C49	Mesothelial & Soft tissue		15	14	29
C451	8720/6	Malignant melanoma, metastatic, NOS	0	1	1
C459	8000/3	Neoplasm, malignant	1	0	1
C473	9560/3	Neurilemoma, malignant	0	1	1
C480	8850/3	Lip sarcoma, NOS	0	1	1
	8858/3	Dedifferentiated lip sarcoma	1	0	1
C482	8140/3	Adenocarcinoma, NOS	0	1	1
	8851/3	Lip sarcoma, well differentiated	1	0	1
C490	8090/3	Basal cell carcinoma, NOS	1	0	1
	8805/3	Undifferentiated sarcoma	0	1	1
	9120/3	Hemangiosarcoma	1	0	1
C491	8851/3	Lip sarcoma, well differentiated	1	0	1
	9040/3	Synovial sarcoma, NOS	1	0	1
	9180/3	Osteosarcoma, NOS	0	1	1
C492	8071/3	Squamous cell carcinoma, keratinizing, NOS	1	0	1
	8801/3	Spindle cell sarcoma	1	0	1
	8801/6	Spindle cell sarcoma, metastatic	2	0	2
	8805/3	Undifferentiated sarcoma	0	1	1
	8850/3	Lip sarcoma, NOS	1	0	1



2021 HOSPITAL-BASED CANCER REGISTRY ANNUAL REPORT



61

TABLE 66 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2021

ICD-10	Code	Morphology Description	Number of cases		
			Male	Female	Total
	8851/3	Lip sarcoma, well differentiated	0	1	1
	8858/3	Dedifferentiated lip sarcoma	0	1	1
C493	9040/6	Synovial sarcoma, metastatic, NOS	0	1	1
C494	8850/3	Lip sarcoma, NOS	0	1	1
C495	9260/3	Ewing sarcoma	1	0	1
C496	8850/3	Lip sarcoma, NOS	1	0	1
C499	8010/3	Carcinoma, NOS	0	1	1
	8010/6	Carcinoma, metastatic, NOS	0	1	1
	8801/3	Spindle cell sarcoma	1	0	1
	8803/3	Small cell sarcoma	0	1	1
C50	Breast		2	201	203
C50	8500/6	Infiltrating duct carcinoma, metastatic, NOS	0	1	1
C500	8010/3	Carcinoma, NOS	0	1	1
	8010/6	Carcinoma, metastatic, NOS	0	2	2
	8500/3	Infiltrating duct carcinoma, NOS	0	16	16
C501	8500/3	Infiltrating duct carcinoma, NOS	0	4	4
	8500/6	Infiltrating duct carcinoma, metastatic, NOS	1	0	1
C502	8500/3	Infiltrating duct carcinoma, NOS	0	7	7
C503	8500/3	Infiltrating duct carcinoma, NOS	0	5	5
C504	8010/3	Carcinoma, NOS	0	1	1
	8500/3	Infiltrating duct carcinoma, NOS	0	16	16
	8500/6	Infiltrating duct carcinoma, metastatic, NOS	0	1	1
C505	8500/3	Infiltrating duct carcinoma, NOS	0	3	3
C506	8500/3	Infiltrating duct carcinoma, NOS	0	1	1
C509	8010/3	Carcinoma, NOS	0	4	4
	8010/6	Carcinoma, metastatic, NOS	0	6	6
	8140/6	Adenocarcinoma, metastatic, NOS	0	3	3
	8480/3	Mucinous adenocarcinoma	0	1	1
	8500/3	Infiltrating duct carcinoma, NOS	0	113	113
	8500/6	Infiltrating duct carcinoma, metastatic, NOS	1	15	16
	8520/3	Lobular carcinoma, NOS	0	1	1
C51,C52,C57	Female genital organs		0	5	5
C511	8070/3	Squamous cell carcinoma, NOS	0	1	1
C519	8070/3	Squamous cell carcinoma, NOS	0	1	1
C52	8070/3	Squamous cell carcinoma, NOS	0	1	1
	8140/3	Adenocarcinoma, NOS	0	1	1
C578	8140/3	Adenocarcinoma, NOS	0	1	1



TABLE 66 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2021

ICD-10	Code	Morphology Description	Number of cases		
			Male	Female	Total
C53	Cervix		0	22	22
C530	8140/3	Adenocarcinoma, NOS	0	2	2
	8140/6	Adenocarcinoma, metastatic, NOS	0	1	1
C531	8070/3	Squamous cell carcinoma, NOS	0	5	5
	8071/3	Squamous cell carcinoma, keratinizing, NOS	0	1	1
	8073/3	Squamous cell carcinoma, small cell, non-keratinizing, NOS	0	4	4
C539	8140/3	Adenocarcinoma, NOS	0	1	1
	8010/3	Carcinoma, NOS	0	1	1
	8070/3	Squamous cell carcinoma, NOS	0	4	4
	8070/6	Squamous cell carcinoma, metastatic, NOS	0	1	1
	8140/3	Adenocarcinoma, NOS	0	2	2
C54	Corpus uteri		0	39	39
C541	8010/3	Carcinoma, NOS	0	16	16
	8010/6	Carcinoma, metastatic, NOS	0	1	1
	8140/3	Adenocarcinoma, NOS	0	11	11
	8140/6	Adenocarcinoma, metastatic, NOS	0	1	1
	8310/3	Clear cell adenocarcinoma, NOS	0	1	1
	8380/3	Endometrioid adenocarcinoma, NOS	0	7	7
	8480/3	Pseudomyxoma peritonei	0	1	1
	8930/6	Endometrial stromal sarcoma, NOS	0	1	1
C55	Uterus		0	1	1
C55	8010/3	Carcinoma, NOS	0	1	1
C56	Ovary		0	21	21
C56	8010/3	Carcinoma, NOS	0	7	7
	8010/6	Carcinoma, metastatic, NOS	0	2	2
	8140/3	Adenocarcinoma, NOS	0	1	1
	8140/6	Adenocarcinoma, metastatic, NOS	0	1	1
	8310/3	Clear cell adenocarcinoma, NOS	0	4	4
	8310/6	Clear cell adenocarcinoma, metastatic, NOS	0	1	1
	8380/3	Endometrioid adenocarcinoma, NOS	0	1	1
	8441/3	Sebaceous adenocarcinoma, metastatic	0	1	1
	8620/3	Granulosa cell tumor, malignant	0	1	1
	9014/3	Serous adenocarcinofibroma	0	1	1
9071/3	Yolk sac tumor	0	1	1	
C60, C62-C63	Male genital organs		3	0	3
C601	8070/3	Squamous cell carcinoma, NOS	1	0	1
C609	8070/3	Squamous cell carcinoma, NOS	1	0	1
C629	9085/3	Mixed germ cell tumor	1	0	1






TABLE 66 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2021

ICD-10	Code	Morphology Description	Number of cases		
			Male	Female	Total
C61	Prostate gland		95	0	95
C61	8010/3	Carcinoma, NOS	1	0	1
	8050/6	Papillary carcinoma, metastatic, NOS	1	0	1
	8130/3	Papillary transitional cell carcinoma	1	0	1
	8140/3	Adenocarcinoma, NOS	75	0	75
	8140/6	Adenocarcinoma, metastatic, NOS	16	0	16
	8500/3	Infiltrating duct carcinoma, NOS	1	0	1
C64-C66	Kidney, Renal pelvis & Ureter		24	7	31
C64	8010/3	Carcinoma, NOS	0	1	1
	8010/6	Carcinoma, metastatic, NOS	1	0	1
	8120/6	Transitional cell carcinoma, metastatic, NOS	0	1	1
	8310/3	Clear cell adenocarcinoma, NOS	6	1	7
	8310/6	Clear cell adenocarcinoma, metastatic, NOS	1	0	1
	8312/3	Renal cell carcinoma, NOS	9	3	12
	8312/6	Renal cell carcinoma, metastatic, NOS	2	0	2
C65	8010/3	Carcinoma, NOS	1	0	1
	8010/6	Carcinoma, metastatic, NOS	1	0	1
	8120/3	Transitional cell carcinoma, NOS	0	1	1
	8120/6	Transitional cell carcinoma, metastatic, NOS	1	0	1
	8130/3	Papillary transitional cell carcinoma	1	0	1
C66	8010/6	Carcinoma, metastatic, NOS	1	0	1
C67	Bladder		18	4	22
C670	8010/3	Carcinoma, NOS	2	0	2
	8120/3	Transitional cell carcinoma, NOS	1	0	1
	8130/3	Papillary transitional cell carcinoma	2	0	2
C671	8130/3	Papillary transitional cell carcinoma	2	0	2
	8140/3	Adenocarcinoma, NOS	0	1	1
C672	8130/3	Papillary transitional cell carcinoma	1	0	1
C673	8010/3	Carcinoma, NOS	1	0	1
C674	8010/3	Carcinoma, NOS	2	0	2
	8130/3	Papillary transitional cell carcinoma	0	1	1
	8140/3	Adenocarcinoma, NOS	1	0	1
C679	8010/3	Carcinoma, NOS	3	0	3
	8130/3	Papillary transitional cell carcinoma	0	2	2
	8130/6	Papillary transitional cell carcinoma, metastatic	1	0	1
	8140/3	Adenocarcinoma, NOS	2	0	2
C69-C70	Eye & Meninges		0	1	1
C709	8720/3	Malignant melanoma, NOS	0	1	1





TABLE 66 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2021

ICD-10	Code	Morphology Description	Number of cases		
			Male	Female	Total
C71	Brain		9	0	9
C711	9441/3	Giant cell glioblastoma	1	0	1
	9441/3	Giant cell glioblastoma	1	0	1
C719	8720/6	Malignant melanoma, metastatic, NOS	1	0	1
	9380/3	Glioma, malignant	2	0	2
	9381/3	Gliomatosis cerebri	1	0	1
	9392/3	Ependymoma, anaplastic	1	0	1
	9472/3	Medulloblastoma	1	0	1
C720	8720/3	Malignant melanoma, NOS	1	0	1
C73	Thyroid gland		14	79	93
C73	8010/6	Carcinoma, metastatic, NOS	1	0	1
	8050/3	Papillary carcinoma, NOS	11	55	66
	8050/6	Papillary carcinoma, metastatic, NOS	0	2	2
	8070/3	Squamous cell carcinoma, NOS	1	0	1
	8140/3	Adenocarcinoma, NOS	0	1	1
	8260/3	Papillary adenocarcinoma, NOS	0	6	6
	8260/6	Papillary adenocarcinoma, metastatic, NOS	1	1	2
	8335/3	Follicular carcinoma, minimally invasive	0	6	6
	8341/3	Papillary micro carcinoma	0	3	3
	8342/3	Papillary carcinoma, oxyphilic cell	0	5	5
C74	Adrenal gland		1	0	1
C741	8700/3	Pheochromocytoma, malignant	1	0	1
C76-C79	Other endocrine glands and relate structures		2	2	4
C770	8070/3	Squamous cell carcinoma, NOS	1	0	1
C780	8010/6	Carcinoma, metastatic, NOS	0	1	1
C790	8312/3	Renal cell carcinoma, NOS	0	1	1
C793	9440/3	Glioblastoma, NOS	1	0	1
C80	Without specification of site		2	3	5
C800	8010/3	Carcinoma, NOS	1	0	1
	8010/6	Carcinoma, metastatic, NOS	0	1	1
	8140/6	Adenocarcinoma, metastatic, NOS	0	1	1
C809	8140/6	Adenocarcinoma, metastatic, NOS	1	1	2
C81	Hodgkin's lymphoma		1	5	6
C811	9596/3	Composite Hodgkin and non - Hodgkin lymphoma	0	1	1
	9650/3	Hodgkin's lymphoma, NOS	0	2	2
C817	9596/3	Composite Hodgkin and non - Hodgkin lymphoma	1	0	1
	9650/3	Hodgkin's lymphoma, NOS	0	1	1
C819	9650/3	Hodgkin's lymphoma, NOS	0	1	1



TABLE 66 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2021

ICD-10	Code	Morphology Description	Number of cases		
			Male	Female	Total
C82-C88	Non - Hodgkin's lymphoma		29	47	76
C824	9680/3	Malignant lymphoma, large B-cell, diffuse, NOS	0	1	1
C827	9596/3	Composite Hodgkin and non - Hodgkin lymphoma	0	1	1
	9695/3	Follicular lymphoma, grade 1	0	1	1
	9596/3	Composite Hodgkin and non - Hodgkin lymphoma	0	1	1
	9695/3	Follicular lymphoma, grade 1	0	1	1
C829	9698/3	Follicular lymphoma, grade 2	0	1	1
C830	9591/3	Malignant lymphoma, non - Hodgkin, NOS	1	0	1
	9596/3	Composite Hodgkin and non - Hodgkin lymphoma	3	1	4
	9596/6	Composite Hodgkin and non - Hodgkin lymphoma, metastatic	2	0	2
C833	9591/3	Malignant lymphoma, non - Hodgkin, NOS	0	2	2
	9596/3	Composite Hodgkin and non - Hodgkin lymphoma	2	8	10
	9596/6	Composite Hodgkin and non - Hodgkin lymphoma, metastatic	2	3	5
	9695/6	Follicular lymphoma, grade 1, metastatic	1	0	1
	9680/3	Malignant lymphoma, large B-cell, diffuse, NOS	1	4	5
	9680/6	Malignant lymphoma, large B-cell, diffuse, metastatic, NOS	0	1	1
	9684/3	Malignant lymphoma, large B-cell, diffuse, immunoblastic, NOS	1	0	1
C839	9596/3	Composite Hodgkin and non - Hodgkin lymphoma	1	0	1
C84	9702/3	Mature T-cell lymphoma, NOS	0	1	1
C840	9700/3	Mycosis fungoides	1	0	1
	9827/3	Adult T-cell leukemia/lymphoma	1	1	2
C8448	9680/3	Malignant lymphoma, large B-cell, diffuse, NOS	0	1	1
C846	9714/3	Anaplastic large cell lymphoma T-cell and Null cell type	0	1	1
C848	9680/3	Malignant lymphoma, large B-cell, diffuse, NOS	1	0	1
	9714/3	Anaplastic large cell lymphoma T-cell and Null cell type	0	1	1
C851	9680/3	Malignant lymphoma, large B-cell, diffuse, NOS	1	1	2
	9680/6	Malignant lymphoma, large B-cell, diffuse, metastatic, NOS	0	1	1
C852	9591/3	Malignant lymphoma, non - Hodgkin, NOS	1	0	1
C859	9591/3	Malignant lymphoma, non - Hodgkin, NOS	1	1	2
	9591/6	Malignant lymphoma, non - Hodgkin, metastatic, NOS	0	1	1
	9596/3	Composite Hodgkin and non - Hodgkin lymphoma	3	6	9
	9596/6	Composite Hodgkin and non - Hodgkin lymphoma, metastatic	1	0	1
	9670/6	Malignant lymphoma, small B lymphocytic	0	1	1
	9680/3	Malignant lymphoma, large B-cell, diffuse, NOS	0	1	1
C860	9719/3	NK/T-cell lymphoma and nasal-type	0	1	1
C863	9708/3	Subcutaneous panniculitis-like T-cell lymphoma	1	0	1
	9827/3	Adult T-cell leukemia/lymphoma	1	1	2
C884	9680/3	Malignant lymphoma, large B-cell, diffuse, NOS	2	0	2
D460	9987/3	Therapy-related myelodysplastic syndrome, NOS	0	1	1
D473	9962/3	Essential thrombocythemia	1	1	2
D693	9962/3	Essential thrombocythemia	0	1	1



TABLE 66

DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2021

ICD-10	Code	Morphology Description	Number of cases		
			Male	Female	Total
C90	Multiple myeloma		16	10	26
C900	9680/3	Malignant lymphoma, large B-cell, diffuse, NOS	1	1	2
	9732/3	Multiple myeloma	11	9	20
	9732/3	Multiple myeloma	2	0	2
	9835/3	Precursor cell lymphoblastic leukemia, NOS	1	0	1
C903	9733/3	plasma cell leukemia	1	0	1
C91-C95	Leukaemia		29	21	50
C910	9801/3	Acute Leukaemia, NOS	1	1	2
	9835/3	Precursor cell lymphoblastic leukemia, NOS	3	2	5
C911	9823/3	B-cell chronic lymphocytic leukemia/small lymphoma	2	0	2
C914	9835/3	Precursor cell lymphoblastic leukemia, NOS	0	1	1
C918	9680/3	Malignant lymphoma, large B-cell, diffuse, NOS	0	1	1
C920	9801/3	Acute Leukaemia, NOS	2	2	4
	9801/3	Acute Leukaemia, NOS	10	8	18
	9861/6	Acute myeloid Leukaemia, metastatic, NOS	1	0	1
	9863/3	Chronic myeloid Leukaemia, NOS	1	0	1
C921	9861/3	Acute myeloid Leukaemia, NOS	0	3	3
	9863/3	Chronic myeloid Leukaemia, NOS	3	2	5
	9945/3	Chronic myelomonocytic Leukaemia, NOS	0	1	1
C924	9835/3	Precursor cell lymphoblastic leukemia, NOS	1	0	1
C927	9861/3	Acute myeloid Leukaemia, NOS	1	0	1
C928	9861/3	Acute myeloid Leukaemia, NOS	1	0	1
C946	9961/3	Myeloproliferative disease	1	0	1
C950	9835/3	Precursor cell lymphoblastic leukemia, NOS	1	0	1
	9861/3	Acute myeloid Leukaemia, NOS	1	0	1





New cancer patients 2017-2021

TABLE 67 DISTRIBUTION OF NEW CANCER PATIENTS BY FOLLOW UP AND GENDER: 2017-2021

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	2436	59.0	2896	73.7	5332	66.2
Deaths	1695	41.0	1032	26.3	2727	33.8
Total	4131	100.0	3928	100.0	8059	100.0

Survey: 5 April 2022

TABLE 68 THE LEADING PRIMARY SITES OF NEW CANCER BY GENDER: 2017-2021

Ordinal	Primary site	Male		Female		Total	
		Number	Percent	Number	Percent	Number	Percent
1	Breast	18	0.4	943	24.0	961	11.9
2	Trachea, bronchus & lung	588	14.2	353	9.0	941	11.7
3	Colon & Rectum	571	13.8	369	9.4	940	11.6
4	Liver & intrahepatic bile ducts	510	12.3	138	3.5	648	8.0
5	Thyroid gland	101	2.4	406	10.3	507	6.3
6	Non-Hodgkin's lymphoma	245	5.9	197	5.0	442	5.5
7	Prostate gland	438	10.6	0	0.0	438	5.4
8	leukaemia	145	3.5	113	2.9	258	3.2
9	Cervix	0	0.0	253	6.4	253	3.1
10	Skin	104	2.5	108	2.7	212	2.6

Survey: 5 April 2022





TABLE 69 THE LEADING PRIMARY SITES OF NEW CANCER BY FOLLOW UP AND GENDER: 2017-2021

Ordinal	Primary site	Alive		Deaths		Total
		Male	Female	Male	Female	
1	Breast	16	820	2	123	961
2	Trachea, bronchus & lung	206	185	382	168	941
3	Colon & Rectum	406	275	165	94	940
4	Liver & intrahepatic bile ducts	201	45	309	93	648
5	Thyroid gland	93	394	8	12	507
6	Non-Hodgkin's lymphoma	159	146	86	51	442
7	Prostate gland	367	0	71	0	438
8	leukaemia	73	61	72	52	258
9	Cervix	0	188	0	65	253
10	Skin	81	97	23	11	212

Survey: 5 April 2022

TABLE 70 THE 60 MONTHS SURVIVAL TIME (MEDIAN) TOP 6 BY GENDER IN 2017 - 2021

Ordinal	Primary site	Male	Female
1	Breast	13.59	10.17
2	Trachea, bronchus & lung	17.95	15.79
3	Colon & Rectum	14.31	12.55
4	Liver & intrahepatic bile ducts	16.16	16.34
5	Thyroid gland	12.03	12.08
6	Non-Hodgkin's lymphoma	12.25	10.30

Survey: 5 April 2022








FIGURE 32: THE 60 MONTHS SERVIVAL RATE (TOP 6) IN 2017 – 2021





HOSPITAL-BASED CANCER REGISTRY 2021 ANNUAL REPORT

FIGURE 33: THE 60 MONTHS SERVIVAL RATE (TOP 6) BY MALE IN 2017 – 2021










FIGURE 34: THE 60 MONTHS SURVIVAL RATE (TOP 6) BY FEMALE IN 2017–2021



Phramongkutklo Hospital 315 Ratchawithi Rd, Bangkok 10400 Thailand.





PHRAMONGKUTKLAO HOSPITAL

EXCELLENT CENTER
OF CANCER CARE

2021

Oncology Unit and Epidemiology Unit,
Phramongkutklao Hospital.

315 Ratchawithi Road, Bangkok 10400, Thailand.

Tel. : + 66 2763 3925, + 66 2763 3047

Email : ceupmk@hotmail.com

Website : <http://ceu.pmk.ac.th>